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Despite tremendous scientific achievements, cancer remains the second leading 
cause of death in the United States. Metabolic reprogramming has been increasingly 
recognized as a core hallmark of cancer. My dissertation work identified novel diagnostic 
markers and therapeutic targets for human cancers through the study of cholesterol in 
cancer cells.  
Enabled by label-free Raman spectromicroscopy, we performed the first 
quantitative analysis of lipogenesis at single cell level in human patient cancerous tissues. 
Our imaging data revealed an unexpected, aberrant accumulation of esterified cholesterol 
in lipid droplets of high-grade prostate cancer and metastases, but not in normal prostate, 
benign prostatic hyperplasia, or prostatitis. Biochemical and molecular biological studies 
showed that such cholesteryl ester accumulation was a consequence of loss of tumor 
suppressor PTEN and subsequent activation of PI3K/AKT pathway in prostate cancer 
cells. Furthermore, we found that such accumulation arose from significantly enhanced 
uptake of exogenous lipoproteins and required cholesterol esterification. Depletion of 
cholesteryl ester storage using pharmacological inhibitors or RNA interference 







suppressed tumor growth in mouse xenograft models with negligible toxicity. These 
findings open new opportunities for diagnosing and treating late-stage prostate cancer by 
targeting the altered cholesterol metabolism.  
My thesis work also found that cholesterol-rich domains on plasma membranes 
can be used as a marker for the loss of basoapical polarity, one of the earliest changes 
observed in breast neoplasia. Raman microspectroscopy revealed that in polarized acini 
lipids were more ordered at the apical membranes compared to basal membranes, and 
that an inverse situation occurred in acini that lost apical polarity upon treatment with 
Ca2+-chelator EGTA. This method allowed us to detect the disruption of apical polarity 
by dietary breast cancer risk factor, ω6 fatty acid, even when the effect was too moderate 
to permit a conclusive assessment by traditional immunostaining method. Collectively, 
label-free Raman analysis of cholesterol-rich membrane domains in mammary acini 











CHAPTER 1. INTRODUCTION 
Despite tremendous scientific achievements, cancer remains a major global 
burden of disease. According to the most recent data on cancer incidence and mortality 
from the National Cancer Institute, and the Center for Disease Control and Prevention, 
cancer is the second leading cause of death in the United States with a total of 1,660,290 
new cases and 580,350 cancer deaths projected to occur in 2013 [1]. In other words, in 
every one minute there is one person dying from cancer in the United States. With 
significant improvements in prevention and control of cardiovascular diseases, cancer 
may soon become the number one killer to human beings worldwide.  
Since the first observation of chromosomal abnormalities in cancers [2] and 
numerous following studies on genetic transformations responsible for carcinogenesis [3-
5], cancer has been classically considered as a multistep genetic disease caused by a 
series of abnormal activation of oncogenes and/or inactivation of tumor suppressor genes 
[6]. Although Warburg discovered a characteristic metabolic pattern for cancer as early 
as 1920s [7], metabolic reprogramming has long been underappreciated by the majority 
of cancer researchers. Owing to recent advances in analytic tools and progress of cancer 
genomics, many key oncogenic transformations in cancer cells have been found to drive 
metabolic signaling pathways that differ from their normal counterparts by high rates of 





Meanwhile, some of the metabolic alterations become necessary for malignant 
transformations [8]. Such connections between oncogenic transformations and metabolic 
alterations make cancer metabolism one of the most intense areas of research in cancer 
biology. Many excellent review articles have been published recently [8-11]. The 
renewed interest in cancer metabolism is opening translational opportunities for the 
diagnosis [12] and treatment [13] of human cancers. Most if not all cancers have been 
suggested to share the same essential alterations in cell physiology, namely the six 
hallmarks of cancer summarized by Hanahan and Weinberg in 2000 [14]. Metabolic 
reprogramming has been increasingly recognized as a new hallmark of cancer [15].  
While normal cells reply on mitochondrial oxidative phosphorylation to generate 
the energy needed for cellular processes, most cancer cells activate glycolysis even in the 
presence of adequate oxygen, a process known as aerobic glycolysis or Warburg effect 
[16]. Although enough evidence has support the crucial role of aerobic glycolysis in 
cancer development, the underlying mechanism why cancer cells prefer to use glycolysis, 
a very inefficient way to generate ATP, is still under investigation [17]. Other than 
energy metabolism, cancer cells also adapt metabolic pathways to facilitate the 
biosynthesis of macromolecules needed for a new cell. The advances in proteomics 
greatly stimulated research, revealing the key roles of amino acids, especially glutamine 








1.1 Fat and Cancer 
Whereas alterations to metabolism of glucose and amino acids have been 
extensively studied [16, 18, 20], the metabolism of another essential macromolecule, 
lipids, in cancer is an under-studied field [21]. Lipids are a group of water-insoluble 
molecules that include fatty acids, sterols, phospholipids, sphingolipids, TGs, etc. [22] 
Phospholipids, together with sterols and sphingolipids, form building blocks of biological 
membranes. TGs serve as energy storage for cells. Fatty acids provide hydrocarbon 
chains to produce more complex lipids, and in the meanwhile can be oxidized into acetyl-
CoA for further biosynthesis or energy supply if no glucose is available. Emerging 
evidence also supports that lipids can also function as signaling molecules that have 
profound effect on a wide range of biological processes, including cell proliferation, cell 
differentiation, apoptosis, migration, and inflammation [23]. Recently, lipids have 
received considerable amount of attention in the field of cancer research, largely due to 
increasing evidence on the link between obesity, dietary fat intake, blood lipid levels and 
cancer risk. 
 
1.1.1 Whole-body Fat Metabolism and Cancer 
Obesity is a strong risk factor for many prevalent metabolic diseases, including 
cardiovascular disease, type 2 diabetes, and cancer [24-28]. Obesity has been reported to 
increase rates of both cancer incidence and mortality for a variety of cancers, including 
those of the oesophagus [29], colorectum [30], postmenopausal breast [31], endometrium 
[32], kidney [33], pancreas [34], liver [35], gallbladder [36], lung [37], cervix [38], ovary 





deaths from cancer in men and 20% of those in women may be due to obesity in the U.S. 
The currently proposed factors linking obesity to cancer include insulin resistance, 
endogenous sex steroids, and adipokines [42]. Accumulating evidence supports that 
dietary fat intake is also positively associated with the risk of CRC, PCa, and BrC, but 
with much less compelling data for other types of cancers [43-47]. Recently, it has been 
recognized that specific types of fats play a much more important role in cancer 
development and progression compared to the total amount of fat intake. Particularly, 
whereas ω-3 PUFAs, including ALA, EPA, and DHA, are precursors for anti-
inflammatory mediators, ω-6 PUFAs, including LA and AA are precursors for pro-
inflammatory mediators [23]. The ratio between ω-6 and ω-3 PUFAs is generally 
believed to positively correlate with cancer risk [48-50]. A positive correlation between 
serum TG levels and the risk of cancers, including lung, colorectal, thyroid, prostate, 
breast, endometrial, and gynaecological cancers, has also been reported [51-55], although 
there are still some inconsistency among different studies [56-58].  
 
1.1.2 Intracellular Fatty Acid Metabolism and Cancer 
Most normal cells acquire lipids from exogenous supplies either in the form of 
FFAs or in the form of LDLs [59]. These exogenous lipids derive from both dietary fat 
intake and the lipids synthesized in the liver or adipose tissue. De novo fatty acid 
synthesis mainly occurs in the liver, adipose tissue, and lactating breast [59]. The TCA 
cycle, fueled by both glycolysis and glutaminolysis, produces citrate, which is converted 
into acetyl-CoA by ACLY. Acetyl-CoA is then catalyzed by ACC to produce malonyl-





generate saturated fatty acid, palmitic acid [60]. Saturated fatty acids can be further 
elongated through catalyzation by enzymes ELOVLs. Fatty acyl-CoA desaturases, 
including SCDs, can introduce one double bond to produce mono-unsaturated fatty acids 
[60]. Because essential PUFAs cannot be synthesized de novo, highly unsaturated fatty 
acids are produced by desaturation of essential PUFAs obtained exogenously [60]. 
1.1.2.1 De Novo Fatty Acid Synthesis in Cancer Cells 
Cancer cells adopt metabolic pathways that differ from their normal counterparts 
by high rates of de novo fatty acid synthesis to fuel rapid growth. The important role of 
de novo lipid synthesis in cancer cell biology has not been recognized until 1990s, when 
oncogenic antigen-519 (OA-519), later known as FASN, was found in cancer cells from 
BrC patients with poor prognosis [61]. Since then, upregulation of several lipogenic 
enzymes in cancer cells has been reported [21, 62] (Figure 1.1). ACLY has been shown 
to be important for cell transformation, proliferation and survival in vitro and 
tumorigenesis in vivo [63, 64]. ACC has also been reported to be overexpressed in BrC 
[65] and crucial for PCa cell growth and survival [66]. FASN, which catalyses the 
terminal steps of de novo fatty acid synthesis, represents the most frequently altered 
lipogenic enzyme in cancer cells [62]. Upregulation of FASN has been shown in many 
types of human cancers and their pre-neoplasia lesions, including breast, prostate, lung, 
oral, colorectum, ovary, oesophagus, melanoma, etc [62].  
Two major mechanisms have been proposed to account for FASN overexpression 






Figure 1.1 Regulation of lipid metabolism by oncogenic signalling pathways. 
Many cancer cells show high rates of de novo lipid synthesis. Fatty acids are 
required for the production of phosphoglycerides, which, together with 
cholesterol, can be used for building cell membranes. Triacylglycerides and 
cholesterylesters are stored in LDs. Lipids from extracellular sources can also 
be used for these purposes. Fatty acids mobilized from lipid stores can be 
degraded in the mitochondria through b-oxidation to provide energy when 
required. Many enzymes within the fatty-acid and cholesterol-biosynthesis 
pathways are regulated by SREBPs (highlighted by yellow boxes). Oncogenic 
activation of the PI3K/Akt pathway promotes glucose uptake and its use in 
lipid synthesis through activation of SREBP. Activation of E2F following loss 
of the retinoblastoma protein increases expression of SREBPs and their target 
genes. Mutant p53 (p53mut) increases the expression of genes within the 
cholesterol biosynthesis (mevalonate) pathway by binding to their promoters. 
AMPK is activated in response to low cellular energy levels and prevents lipid 
synthesis and stimulates b-oxidation through inhibition of ACC. AMPK can 
also inhibit SREBP by direct phosphorylation. Activation of HIF1 by hypoxia 
reduces the flux of glucose to acetyl-CoA through the mitochondria. 
Reductive metabolism of glutamine-derived a-ketoglutarate provides 
cytoplasmic citrate in hypoxic cells. Reprinted with permission from [21]. 






as EGFR (also known as ERBB1) and ERBB2 (also known as HER2), activates the 
downstream signaling pathways, including PI3K–AKT and MAPK-ERKs (ERK1 and 
ERK2) transduction cascades [62] (Figure 1.1). Another possible mechanism is through 
steroid hormones, including estrogen, progestin, and androgen, and their corresponding 
receptors, i.e. ER, PR, and AR. The binding of steroid hormones to their receptors also 
activates the identical downstream pathways [62] (Figure 1.1). Both PI3K-AKT and 
MAPK-ERK pathways have been found upregulated and implicated in cancer 
pathogenesis [67, 68]. These two oncogenic signaling pathways regulate FASN 
expression through SREBPs [69] (Figure 1.1). The SREBPs are transcription factors that 
function to control lipid and cholesterol homeostasis by sensing cellular cholesterol [70]. 
Activation of SREBP has been frequently observed in a number of cancers. The three 
SREBP isoforms, SREBP-1a, -1c, and -2, have different roles in lipid synthesis. Whereas 
SREBP-1a and -2 are relatively specific to cholesterol synthesis, SREBP-1c is 
responsible for de novo fatty acid synthesis [71].  
Increased de novo fatty acid synthesis renders new therapeutic targets for cancer 
treatment [21, 72]. Among all the overexpressed lipogenic enzymes, FASN is the most 
attractive target due to its universal upregulation in various types of cancers [62]. Several 
FASN inhibitors have been developed, including C75, orlistat and GSK837149A, and the 
current data suggest the potential of FASN to be a good clinical target [62]. Nevertheless, 
the side effect of FASN inhibition on central nervous system raises significant concerns 





1.1.2.2 Lipid Hydrolysis in Cancer Cells 
The majority of research on altered lipid metabolism in cancer has been focusing 
on de novo fatty acid synthesis until the recent finding of MAGL, a lipolytic enzyme that 
is highly elevated in aggressive cancer cells from multiple tissues of origin [73, 74] 
(Figure 1.1).  MAGL hydrolyzes monoacylglycerols to release FFAs, which were found 
to correlate with aggressiveness of cancer cells [73, 74]. MAGL inhibition by inhibitor 
JZL184 or shRNA was shown to significantly suppress cancer cell proliferation, 
migration, invasion, and growth in vivo [73, 74]. Nevertheless, the inhibitory effect of 
MAGL inhibition on cancer growth was restored by high-fat diet [73]. Further studies are 
needed to clarify whether the functions of fatty acids derived from de novo synthesis or 
released from lipolysis are different. This may address the concern about simultaneous 
increase of both lipogenesis and lipolysis.  
1.1.2.3 FFAs Promote Cancer Development 
FFAs have been shown to promote different aspects of cancer development [21, 
72] (Figure 1.1). First, quite a number of FFAs are esterified to phospholipids, which are 
important structural lipids for membrane synthesis. Second, FFAs are oxidized during 
periods of energy stress. As an example, PCa generally displays low levels of glycolysis 
and high levels of β-oxidation enzymes [75]. Increased β-oxidation has also been found 
in pancreatic cancer, leukaemia, and glioblastoma cells [21, 72]. Third, FFAs provide 
sources for derivative signaling lipids, such as phosphatidic acid, lysophosphatidic acid, 
prostaglandins, and leukotrienes. Lysophosphatidic acids promote cell aggressiveness 





leukotrienes have been implicated in a variety of human malignancies, including 
inflammation and carcinogenesis [77]. In addition, FFAs also contribute to other aspects 
of cancer biology, such as redox homeostasis and resistance to oxidative stress [21, 72].  
1.1.2.4 Neutral Fat Storage in Cancer Cells 
Neutral fat are stored in LDs, an organelle that has a monolayer of phospholipid 
and specific proteins [22]. Cells contain various types of LDs with distinct functions due 
to the proteins attached, such as LD structural proteins, lipid synthesis enzymes, lipases, 
and membrane-trafficking proteins. LDs often play dynamic roles in various aspects of 
lipid metabolism [78-80]. The aberrant accumulation of LDs is associated with some of 
the most widespread human diseases, such as obesity, diabetes type II, and 
atherosclerosis [81].  
Based on the findings of upregulated expressions of both lipogenic and lipolytic 
enzymes, it is conceivable that cancer cells require reservoirs for lipids, namely LDs, to 
store newly synthesized lipids on one hand and provide lipids for hydrolysis on the other 
hand. Indeed, as early as the 1970s, LDs were reported in clinical studies of mammary 
carcinoma [82]. Since then, lipid accumulation has been described in many types of 
human cancers, including breast, brain, colon and others [83-85]. For CRC, LDs were 
found to serve as reservoirs of cyclooxygenase 2 and prostaglandin synthase [84], which 
have been shown to be implicated in various human malignancies including inflammation 
and cancer [86]. For PCa, LD accumulation in LNCaP-LP was reported and attributed to 
the upregulation of fatty acid synthase [87, 88]. Lipid accumulation was also shown to 






[90], lipid accumulation has not, to date, been used as a prognostic factor or 
therapeutic target of cancer. In particular, because compositions of LDs are not 
readily accessible with traditional methods, the exact role of lipid accumulation in 
cancer progression remains elusive.  
 
1.2 Cholesterol and Cancer 
Cholesterol is an essential biomolecule that plays important roles in the 
maintenance of membrane structure, signal transduction, and provision of precursor to 
hormone synthesis [91]. Although there has been an undoubted link between cholesterol 
and cardiovascular disease [92], the role of cholesterol in cancer remains elusive. This 
key section will thoroughly review the current understanding of cholesterol metabolism 
in cancer at both whole-body and cellular levels. 
 
1.2.1 Whole-body Cholesterol Metabolism and Cancer 
Cholesterol can be acquired from diet or endogenous biosynthesis. Dietary 
cholesterol is absorbed by enterocytes of the small intestine and is further packaged into 
the lipoprotein chylomicrons, which after addition of new apoproteins are taken up by 
hepatocytes of the liver [93]. Along with the cholesterol synthesized de novo by the liver, 
hepatocytes secrete cholesterol in VLDL particles that are further processed into LDL [59, 
93]. LDLs contain the most cholesterol content among all lipoproteins and deliver 
cholesterol into periphery tissues for key biological processes. Excess cholesterol from 







1.2.1.1 Dietary Cholesterol Intake and Cancer Risk 
Dietary Healthy dietary pattern (e.g. low in red meat, high in vegetable) has been 
recommended to prevent cancer [94]. In order to determine the contribution of dietary 
cholesterol intake to cancer risk, a number of epidemiological studies have been 
conducted. By evaluating food frequency questionnaire, one study has reported that 
dietary cholesterol intake is associated with increased risk of various types of cancers, 
including lung, breast, colon, rectum, stomach, pancreas, kidney, and bladder cancers 
[95]. A population-based case-control study from Japan also concluded that diet rich in 
cholesterol increased pancreatic cancer risk [96]. In contrast, a cohort study of US 
women did not support the association between cholesterol intake and pancreatic cancer 
risk [97]. In terms of CRC, a number of studies consistently show that dietary cholesterol 
significantly increases the risk of CRC [98-100]. Animal study has also shown that 
dietary cholesterol is a potent dietary co-carcinogen that promotes carcinogenesis of CRC 
in rats [101, 102], and reduced intake of cholesterol suppresses CRC metastasis and 
prolongs survival in the rat model [103]. For the squamous and small cell lung cancer 
patients who smoke tobacco heavily in Hawaii, cholesterol intake was found to increase 
the risk of lung cancer [104]. Another study from Hawaii also supports the role of dietary 
cholesterol intake in lung cancer in men but not in women [105, 106]. However, in the 
studies conducted among Japanese men in Hawaii and Finnish men, no association was 
observed between cholesterol and lung cancer risk [107, 108]. A pooled analysis of 12 
cohort studies did not find a correlation between cholesterol or egg intake and the risk of 
OvC [109]. Dietary cholesterol did not significantly contribute to mammary tumor 






cancer may exist, but it might depend on cancer types. More systematic clinical and 
preclinical studies are needed.  
 
1.2.1.2 Blood Cholesterol Levels and Cancer Risk 
Based on the large prospective study on cholesterol and cancer conducted in 
Korea, the relationship between total-C levels and cancer has varied greatly by tissue of 
origin [111]. Whereas total-C levels were positively associated with the risk of BrC, PCa, 
and CRC, total-C levels were negatively correlated with the risk of cancers arising from 
liver, lung, stomach, and esophageal [111]. A few other studies also suggest that cancer 
patients have declined levels of cholesterol in the blood [112-115]. The cholesterol 
fraction associated with the decrease in circulating cholesterol was majorly HDL-C [116]. 
The decreased level of HDL-C has been found to be restored when cancer is in the 
remission stage [117]. Because the association between circulating cholesterol levels and 
cancer risk varies by cancer types, we will review in more details for the most heavily 
studied cancer types as below.  
PCa is certainly the most extensively studied cancer type with respect to the 
effects of circulating cholesterol levels. A number of prospective studies show that men 
with low circulating cholesterol are at lower risk of developing high-grade PCa (Gleason 
score 8-10) compared to those with high cholesterol levels. No correlation between 
circulating cholesterol levels and the risk of overall or low-grade PCa (Gleason score 2-6) 
was found [118-120]. Consistently, men with high cholesterol levels (≥ 240 mg/dL) had 






(< 200 mg/dL) [121]. Although there was one study that did not find association between 
cholesterol levels and PCa [122], its follow-up study concluded that HDL-C levels were 
inversely associated with PCa risk [123]. It was also observed that both total-C/HDL-C 
and LDL-C/HDL-C ratios were associated with increased risk of PCa [123]. High HDL-
C levels were also found to prevent against PCa in another study [124]. All these 
epidemiological evidence supports the positive association between hypercholesterolemia 
and risk of aggressive PCa.  
Preclinical studies also support the role of cholesterol in PCa incidence and 
progression. Zhuang et al. [125] and Mostaghel et al. [126] both demonstrated that 
elevation of circulating cholesterol in nude mice promoted tumor growth, by increasing 
either the phosphorylation of AKT (a key kinase in PCa survival and growth) or the 
intratumoral de novo steroidogenesis. Solomon et al. [127] showed that the 
pharmacological reduction of serum cholesterol levels hindered human PCa growth in a 
mouse xenograft model. Spontaneous PCa models (e.g. TRAMP) have also been used to 
strengthen the conclusion that hypercholesterolemia results in enhanced tumor 
progression and metastases to the lung [128]. 
BrC has higher incidence in western countries, which leads to a focus on the link 
between diet and BrC risk. Although dietary fat intake affects blood cholesterol levels, it 
is not conclusive that blood cholesterol levels contribute to the overall BrC risk. In the 
Nurses' Health Study, serum cholesterol levels were not substantially associated with BrC 
risk [129]. In a prospective study of postmenopausal women conducted in Korea, a 
positive correlation between serum cholesterol levels and BrC incidence was found, but 






[130]. In another study conducted in Sweden, high cholesterol levels were found to be a 
risk factor for postmenopausal women but not for premenopausal women [131]. 
Circulating cholesterol also affects clinical outcome of BrC. A prospective study of 
Canadian women reported a high recurrence rate in women with high cholesterol levels 
[132]. Another study of Norwegian women shows an increased death from BrC in 
women who were in the highest quartile of cholesterol levels [133]. It was also found that 
postmenopausal BrC patients had higher oxLDL, total-C, and LDL-C levels compared to 
the matched healthy women [134]. The results from epidemiological studies are still not 
conclusive, because different BMI or BrC sub-type results in different circulating 
cholesterol.  
Fewer studies have been performed on the link between cholesterol and other 
types of cancer. For OvC, late-stage patients who had normal LDL-C survived 
significantly longer than those who had elevated LDL-C [135]. Higher oxLDL levels 
were also found in women with OvC compared to the matched control group [134]. In 
terms of CRC, a prospective study conducted in Europe found a negative trend for HDL-
C with CRC, but no significant trend for total-C or LDL-C with CRC [136]. The Japan 
Collaborative Cohort Study did not find an association between total-C and CRC neither 
[137], even though oxLDL was significantly higher in CRC patients. Nevertheless, higher 
levels of total-C, LDL-C and LDL/HDL ratios were observed in CRC patients with 







1.2.1.3 Statin Use and Cancer Risk 
As blood cholesterol levels have been shown to be closely correlated with cancer 
risk, it is conceivable that cholesterol-lowering drugs may prevent cancer development. 
Indeed use of statins, HMGCR inhibitors that lower blood cholesterol levels via blocking 
cholesterol synthesis in the liver, has been found to reduce the risk of cancer incidence 
and mortality [139-141].  
PCa is certainly the most extensively studied cancer type for the effect of statins 
on cancer risk [142, 143]. Although there have been some conflicting results, with one 
study showing no association [144] and two studies reporting a positive association 
between statin use and PCa risk [145, 146], many more studies have collectively support 
a protective effect of statins [143]. In 2006, a large prospective cohort study of US male 
health professionals, for the first time, demonstrated a protective effect of statins on the 
risk of advanced PCa [147]. Specifically, although no association between statin use and 
risk of PCa overall was found, current use of statins was shown to reduce risk of 
advanced PCa by 49% and of metastatic or fatal PCa by 61%, compared with no current 
use. Longer use of statins (≥ 5 years) was associated with even lower risk of advanced 
disease (0.26, 95% CI = 0.08 to 0.83). One year later, the California Men's Health Study 
showed that long-term use (≥ 5 years) of statins was associated with a 28% lower risk for 
PCa compared to nonuse, among regular nonsteroidal anti-inflammatory drug users [148]. 
According to a large U.S. cohort study (Cancer Prevention Study II Nutrition Cohort), 
long-term use (≥ 5 years) of statins was also found to reduce the risk of advanced PCa, 
even though not associated with overall PCa incidence [144, 149]. A population-based 






atorvastatin, lovastatin, and simvastatin, had significantly lower risk of developing 
advanced PCa [150]. Recently, more reports have shown the positive correlation between 
statin use and reduced risk of high-grade PCa [151, 152]. Based on the data in Veterans 
Affairs New England Healthcare System, statin users were 31% less likely to be 
diagnosed with PCa and 60% less likely to be diagnosed with high-grade PCa, compared 
with antihypertensive medication users [153]. Studies also found that statin users were 
less likely to have high PSA levels [154] or develop high-grade PIN [155]. Statin use was 
associated with a significant improvement in PSA relapse-free survival in high-risk 
patients who received radiotherapy [156], and reduced risk of recurrence after 
prostatectomy [157] and death from PCa [158]. Collectively, these studies strongly 
support the hypothesis that statins reduce the risk of advanced PCa. 
A number of clinical trials have been conducted to evaluate the effect of statins on 
BrC risk. The majority of earlier studies did not find an association between statin use 
and BrC risk [159]. Several recent epidemiologic studies showed promising results of 
statin use in BrC prevention [160-162]. The reason for this inconsistency is possibly that 
earlier studies analyzed all statin users as a single group, whereas the recent studies 
compared clinical outcomes for different types of statins (e.g. hydrophilic, hydrophobic) 
[163]. One of the most recent study, Danish Nationwide Prospective Cohort Study), 
showed that use of hydrophobic statins reduced both incidence and recurrence of BrC 
over 10-year follow-up [160]. Other two studies also supported the protective effect of 
hydrophobic statins on BrC incidence [162] and recurrence [161]. A recent cohort study 






progression-free survival [164]. A prospective randomised study evaluating the benefits 
of certain types of statins in BrC is warranted.  
Fewer studies have been performed to evaluation the association between statin 
use and the risk of other types of cancer. There was one earlier study reporting 47% 
reduction in CRC incidence associated with long-term use of stains [165]. Unfortunately, 
later studies with mixed results could not reproduce this finding [166]. A 55% reduction 
in the incidence of lung cancer was found in statin users [167]. However, this finding was 
argued to be misleading due to a failure of correcting immortal time bias [168]. For OvC, 
statin use was found to be associated with longer progression-free and overall survival in 
women diagnosed with stage III/IV OvC [169].  
The mechanism by which statins prevent cancer is an intense area of research. 
Statins are inhibitors of HMGCR, thus blocking the entire mevalonate pathway. As a 
result, not only cholesterol synthesis but also other cholesterol-independent reactions, 
including G-protein posttranslational modification, are inhibited by statins [139]. G-
protein (e.g. Ras, Rac, and Rho) posttranslational modification has been shown to 
enhance many oncogenic events including cell proliferation and metastatic potential 
[139]. Nevertheless, it has been proposed that the protective effect of statins on cancer in 
vivo is largely attributed from their cholesterol-lowering capabilities [140, 143] instead of 
the local effects on cancer cells. 
 
1.2.2 Intracellular Cholesterol Metabolism and Cancer 
Inside cells, cholesterol is an essential molecule that plays important roles in the 






hormone synthesis [93]. Cholesterol can be either de novo synthesized via the mevalonate 
pathway or taken up from exogenous lipoproteins LDL [93]. LDL is known to enter a cell 
via LDLr and traffic to the late endosome and lysosome to be hydrolyzed to free fatty 
acids and free cholesterol. The excess free cholesterol together with the fatty acyl CoA 
substrate is converted to CE by ACAT and stored in LDs [170] (Figure 1.2). 
 
Figure 1.2 Intracellular cholesterol regulation. Cholesterol enters cells via LDLr-
mediated endocytosis. CE in LDL is hydrolyzed to FC and FFAs in late endosome and 
lysosome system. Together with cholesterol synthesized de novo in the ER, excess FC is 
esterified into CEs and stored in LDs or effluxed to extracellular acceptors, such as HDL. 
FC majorly locates on plasma membranes. HSL is used for neutral lipid hydrolysis to 
mobile lipids for important signaling pathways. 
 
1.2.2.1 Cholesterol Synthesis, Uptake, and Efflux in Cancer Cells 
Whereas synthesis and uptake increase cellular cholesterol levels, efflux reduces 






steps in cholesterol synthesis. A number of studies have shown that HMGCR is 
upregulated in many types of cancer cells and HMGCR inhibition leads to growth arrest 
and apoptosis [171-174]. With respect to cholesterol uptake, over-expression of LDLR 
has been observed in many types of aggressive cancer cells, including metastatic PCa 
[175, 176],  ER- BrC [177, 178], and glioblastoma [179]. ABCA1 and ABCG1 are the 
major regulatory proteins for cholesterol efflux. ABCA1 downregulation was found in 
high-grade PCa tissues but not in benign prostate, and expression levels of ABCA1 were 
inversely associated with Gleason grades [180]. 
1.2.2.2 Cholesterol Homeostasis in Cancer Cells 
Intracellular cholesterol homeostasis is regulated by two master transcriptional 
factors, the SREBP and LXR. The regulation of SREBP activity and the role of SREBP 
in cell metabolism have been thoroughly explored [70, 181]. In brief, when cellular 
cholesterol levels are low, SREBP gets activated and the cleaved form of SREBP 
migrates into nucleus to upregulate target genes, including HMGCR and LDLr, to 
promote cholesterol synthesis and uptake. SREBP has three isoforms, SREBP-1a, -1c, 
and -2, which play different roles in lipid synthesis. SREBP-1c is responsible for fatty 
acid synthesis, whereas SREBP-1a and -2 are relatively specific to cholesterol synthesis 
[71]. When cellular cholesterol levels are high, free cholesterol is oxidized to form 
oxysterols. The increased levels of oxysterols can be sensed by LXR, which activates 
MYLIP/IDOL for LDLr degradation and ABCA1 (or ABCG1) for cholesterol efflux 
[182]. Increased activation of SREBPs has been reported in advanced PCa [183] and 






by reducing cholesterol uptake and increasing cholesterol efflux [179]. LXR agonist has 
also been reported to delay the progression of androgen-dependent PCa to androgen-
independent PCa after castration [184].  
1.2.2.3 Cholesterol as a Precursor of Steroidogenesis in Cancer Cells 
Cholesterol is the common precursor of five different classes of steroid hormones. 
Steroid hormones are generally believed to be synthesized in specialized organs, the 
adrenal glands, testes, and ovaries. Steroid hormones are known to stimulate proliferation 
and differentiation of BrC, PCa, and endometrial cancer cells. Hormonal therapy has 
become standard therapy for several types of cancers. For men with advanced PCa, 
androgen deprivation therapy is an accepted standard therapy. Despite initial disease 
control, androgen deprivation therapy alone is non-curative and the subsequent 
development of castration-resistant PCa occurs in the lifespan of almost all men who do 
not succumb to non-cancer deaths [185]. Increasing evidence supports that androgen 
signaling pathways remain transcriptionally active in castration-resistant PCa [185]. The 
studies collectively demonstrate that castration-resistant PCa cells have the entire 
functional mevalonate-steroidogenesis pathway for de novo DHT synthesis [186-188]. 
Cholesterol has been shown to promote progression of castration-resistant PCa by 
activating the androgen signaling pathway in vivo [189]. These findings suggest that 
cholesterol could be a potential target for castration-resistant PCa [190].  
1.2.2.4 Cholesterol-rich Membrane Domains (Lipid Raft) in Cancer Cells 
The membrane domains rich in sphingolipids and cholesterol are called lipid rafts 






function as hubs for the assembly of signaling molecules and cellular signal transduction 
[191]. Lipid raft signaling has been shown to be involved in various human pathogenesis, 
including cardiovascular disease, neurodegenerative disease, and cancer [192]. The 
essential role of cholesterol accumulation within membrane lipid raft in PCa progression 
has been thoroughly reviewed [193]. Caveolae are omega-shaped invaginations of the 
plasma membrane rich in caveolin protein family, including caveolin-1 [191]. Caveolin-1 
has been implicated in cancer development, progression, and metastasis, particularly in 
PCa [194, 195]. In some cancer types, such as breast cancer, caveolin-1 may act as a 
negative regulator of tumorigenesis [196]. The ambiguous role of caveolin-1 in cancer 
may stimulate further research on the role of membrane lipid raft in cancer. A molecular 
understanding of the contribution of membrane lipid rafts to cancer development 
has assisted the design of effective therapeutic strategies. The utility of membrane 
lipid rafts as diagnostic markers of cancer needs further research. 
1.2.2.5 Cholesterol Esterification and Storage in Cancer Cells 
Increase cholesterol esterification and storage have been reported in leukemia 
[197-201], brain cancer [201-203], clear-cell renal carcinoma [201, 204-206], and BrC 
[177]. Although CE accumulation in foam cells is known to be a hallmark of 
atherosclerosis, its exact clinical and biological role in cancer progression remains 
elusive. Further investigation into clinical relevance of CE accumulation in various 
types of human cancers would determine whether CE is a potential marker for 
cancer diagnosis. Future elucidation of the molecular mechanisms by which CE is 






initiation and progression is also warranted for validation of cholesterol 
esterification as a potential target for cancer treatment.  
In summary, the essential role of cholesterol metabolism in cancer development 
and progression has been increasingly recognized [166, 207-211]. Future study along this 
direction will open new avenue to cancer diagnosis and treatment. 
 
1.3 Current Analytical Tools for Lipid Research 
Conventionally, the investigation of intracellular lipid and its accumulation in 
cancer cells relies on nonspecific, invasive, or population-average measurements. Unlike 
many proteins where there are specific antibodies, most lipid molecules have no known 
specific markers, so fluorescent signals from lipophilic dyes (e.g. ORO for LD staining, 
and DiO or DiI for membrane staining) contain no information regarding lipid 
composition or organization. Similarly, electron microscopy imaging of intracellular lipid 
body lacks compositional information as well.  
To analyze the composition of lipids, standard techniques, including mass 
spectrometry and NMR spectroscopy, have been employed. Although such analytical 
techniques are powerful, they require the most sample preparation and provide only 
population-average information without spatial distribution. The recent development of 
DESI-MS renders information of both lipid composition and spatial distribution [212], 
but the low resolution (~250 μm) hinders its application to cellular studies. Spontaneous 
Raman spectroscopy is another powerful analytical method that has been widely used in 
biomedical research [213-215]. However, spontaneous Raman signals are too weak to be 






One of the major roadblocks that prevent the research of lipids in cancer from 
advancing is a lack of suitable tools for charactering intracellular lipids at single cell level 
in a heterogeneous tissue context. Cancer tissues are known to comprise not only cancer 
cells but also many types of stromal cells, such as fibroblasts and inflammatory cells [15, 
216]. Moreover, human cancer tissues are even more complex because they are very 
likely to contain both benign and cancerous cells with different histological grades within 
the same piece of tissue. Undoubtedly, new methodologies which allow non-invasive, 
compositional, and single-cell measurement of lipids in an intact tissue environment 
are warranted to advance our understanding of the role of intracellular lipids in 
cancer development. 
 
1.4 Label-free Spectroscopic Imaging of Lipids in Single Live Cells 
A portion of the work presented in this section was published in Laser & 
Photonics Reviews [217]. Reprinted with permission from [217]. Copyright © 1999-2013 
John Wiley & Sons, Inc.  
An attractive alternative to dye-labeled assay is coherent Raman microscopy, 
including CARS microscopy and recently developed SRS microscopy (Figure 1.2). Both 
of them are label-free chemical imaging techniques that probe intrinsic molecular 
vibrations. CARS is a NLO process in which the interaction of a pump field Ep(p) and a 
Stokes field Es(s) with a sample generates an anti-Stokes field Eas at the frequency of 
2ps. CARS microscopy is particularly sensitive to lipid-rich structures when the 
beating frequency (ps) of the two pulsed lasers is tuned to 2840 cm







Figure 1.3 Energy diagrams and setup schematic of CARS and SRS 
microscopy, and Raman spectroscopy. Solid lines represent electronic and 
vibrational states of molecules, dashed lines are virtual states. The straight 
arrows are excitation beams, the wavy arrows are output signal beams. The 
gray arrows represent relaxation in electronically excited states. ω1 and ω2 are 
two beams available in the CARS microscope. ωp = ω1 and ωs = ω2 in CARS 
and SRS level diagram. Here SRG is shown as an example for SRS. Ω is a 
frequency of vibrational transition between vibrational ground state v = 0 and 
vibrationally excited state v = 1. ω1 and ω2 are pump and Stokes beams from 
the laser sources, respectively. OM is an optical modulator, SU is a scanning 
mirror unit. DM is an exchangeable dichroic mirror. The inset shows the 
connections between electronic components for phase-sensitive heterodyne 
detection. Lock-in is a lock-in amplifier, PD is a photodiode, PC is a computer, 
FG is a function generator. The blue-colored components are used for 
modalities with homodyne type of detection. The light blue color represents 
components required for modalities with heterodyne detection. The 
spectrometer is used for fingerprint spectral analysis. 
 
the symmetric vibration of CH2 bands. Such single-frequency CARS microscopy has 
been applied to image cellular membranes, myelin sheath, and intracellular lipids with 3D 
and sub-micron spatial resolution [218-222]. Compared to CARS, SRS microscopy offers 
two major advantages: (1) SRS signal is free of the nonresonant background, which 
makes it highly sensitive; (2) SRS signal is linearly proportional to the molecular 






microscopy, the modulations of pump and Stokes beam intensities due to the SRS process 
are usually very small ( 410I I ) as calculated for experimental imaging conditions 
[223]. Therefore, modulation of the excitation beam and phase-sensitive detection 
method are needed to pick the signal out of the laser noise. High-speed SRS microscopy 
has been recently demonstrated [224-229] and applied to vibrational imaging of tablets 
and biomass [230, 231]. We have published a detailed review on coherent Raman 
microscope and its biological applications (please see Ref. [217]). 
In response to the strong demand for a novel technique that can visualize 
intracellular lipids with submicron resolution and analyze their composition in situ, we 
have developed a vibrational spectromicroscope that integrates coherent Raman 
microscopy and spontaneous Raman spectroscopy on the same platform [232]. With the 
capability of vibrational imaging and spectral analysis within a few seconds, vibrational 
spectromicroscope has been applied to analyze intracellular lipids in live tissues and 
obtain important information including lipid amount and size, degree of carbon chain 
unsaturation, and lipid-packing density [233]. We expect this label-free spectroscopic 






CHAPTER 2.  ALTERED CHOLESTEROL METABOLISM: NEW AVENUE TO 
DIAGNOSIS AND TREATMENT OF HUMAN PROSTATE CANCER 
The work presented in this chapter has been submitted to Cell Metabolism. 
Altered lipid metabolism is increasingly recognized as a signature of cancer cells. 
Enabled by label-free Raman spectromicroscopy, we performed the first quantitative 
analysis of lipogenesis at single cell level in human patient cancerous tissues. Our 
imaging data revealed an unexpected, aberrant accumulation of esterified cholesterol in 
LDs of high-grade PCa and metastases. Biochemical and molecular biological studies 
showed that such CE accumulation was a consequence of loss of tumor suppressor PTEN 
and subsequent activation of PI3K/AKT pathway in PCa cells. Furthermore, we found 
that such accumulation arose from significantly enhanced uptake of exogenous 
lipoproteins and required cholesterol esterification. Depletion of CE storage using 
pharmacological inhibitors or RNA interference significantly reduced cancer proliferation, 
impaired cancer invasion capability, and suppressed tumor growth in mouse xenograft 
models with negligible toxicity. These findings open new opportunities for diagnosing 







Cancer cells adopt metabolic pathways that differ from their normal counterparts 
by high rates of glycolysis and biosynthesis of essential macromolecules to fuel rapid 
growth [8]. Among dysregulated metabolic pathways, increased de novo synthesis of 
lipids has become a common characteristic of human cancers [21]. For instance, FASN, 
the key enzyme that catalyzes the terminal steps in fatty acid synthesis, is frequently 
upregulated in human malignancies and plays important roles in cancer pathogenesis [62, 
234]. In parallel with lipogenesis, lipolysis has also been shown to be elevated in multiple 
human cancers [73]. Specifically, MAGL, the lipolytic enzyme that hydrolyzes 
monoacylglycerols to release FFAs, was found to be overexpressed in aggressive cancer 
cells. Based on the findings of upregulated expressions of both lipogenic and lipolytic 
enzymes, it is conceivable that cancer cells require reservoirs for lipids, namely LDs, to 
store newly synthesized lipids on one hand and provide lipids for hydrolysis on the other 
hand. Indeed, as early as the 1970s, LDs were reported in clinical studies of mammary 
carcinoma [82]. Since then, lipid accumulation has been described in many types of 
human cancers, including breast, brain, colon and others [83-85]. Nonetheless, lipid 
accumulation has not, to date, been used as a prognostic factor or therapeutic target of 
cancer. In particular, because compositions of LDs are not readily accessible with 
traditional methods, the exact role of lipid accumulation in cancer progression remains 
elusive.  
LDs are visualized mainly through labeling with lipophilic dyes, which requires 
fixation and lacks compositional information. To assay for lipid composition, analytical 






used. Because such techniques analyze tissue homogenates, it is impossible to obtain 
compositional information of individual LDs inside cells. The recently developed 
coherent Raman scattering microscopy [235] has shed new light on the study of LD 
biology [217, 236], with its label-free detection capability, high imaging speed, and 
submicron spatial resolution. Using this technique, high-speed vibrational imaging of LD 
dynamics in live cells and embryos has been demonstrated [237-241]. Multiplex CARS 
microscopy has been used to study phase separation in LDs of 3T3-L1 cells [242]. 
Coupling the high-speed imaging capability of coherent Raman scattering microscopy 
and full spectral analysis capability of spontaneous Raman spectroscopy allowed 
quantitation of not only the amount, but also the composition, of individual LDs in live 
cells [243].  
Here, we report the first quantitative analysis of lipogenesis at the single cell level 
in intact tissues from a spectrum of human prostate pathologies. Our label-free imaging 
study revealed an unexpected accumulation of CE in high-grade and metastatic human 
PCa tissues, but not in normal prostate, BPH, prostatitis, or PIN tissues. Our biochemical 
study further showed that such CE accumulation was induced by loss of tumor suppressor 
PTEN, upregulation of PI3K/AKT/mTOR pathway, and consequent activation of SREBP 
and LDLr. Pharmacological inhibition of cholesterol esterification significantly 
suppressed cancer proliferation, migration, invasion, and tumor growth in vivo.  These 
data collectively herald the potential of using CE as a marker for diagnosis of aggressive 







2.2 Experimental Section 
2.2.1 Human Prostate Tissue Specimens 
This study was approved by institutional review board. Frozen specimens of 
human prostate tissues derived from patients who underwent radical prostatectomy for 
PCa were obtained from Indiana University Simon Cancer Center Solid Tissue Bank. 
These patients had not received hormone therapy before radical prostatectomy. In 
addition, frozen specimens of normal prostate tissues donated from healthy subjects and 
metastatic PCa tissues collected by warm body autopsy from patients who had failed 
hormone therapy were obtained from Johns Hopkins Hospital. Totally, 19 normal 
prostates, 10 BPH, 3 prostatitis, 3 PIN lesions, 12 low-grade PCa (Gleason grade 3), 12 
high-grade PCa (Gleason grade 4/5), and 9 metastatic PCa [liver (n = 2), lymph node (n = 
3), rib (n = 1), lung (n = 1), adrenal (n = 1), and abdominal soft tissue (n = 1)] from 64 
different patients or healthy donors were analyzed. For each tissue specimen, pairs of 
neighboring slices were prepared, with one slice remained unstained for spectroscopic 
imaging and the other stained with H&E. Pathological examination was made by 
genitourinary pathologists. 
2.2.2 Cell Culture 
K-SFM with additives BPE and hEGF, RPMI 1640, T-medium, and FBS were 
purchased from Invitrogen. F-12K and EMEM were obtained from ATCC. Cells were 
cultured in the following media: RWPE1 in K-SFM supplemented with BPE (0.05 mg/ml) 
and hEGF (5 ng/ml). LNCaP-LP, LNCaP-HP, and 22Rv-1 in RPMI 1640 supplemented 
with 10% FBS. PC-3 in F-12K supplemented with 10% FBS. DU145 in EMEM 






HP was derived upon continuous passage from original LNCaP from ATCC (LNCaP-LP) 
until the passage number was over 60, and is an established cell line of AR-positive but 
androgen-independent PCa [244-247]. 
2.2.3 Chemicals 
LY294002, MK2206, rapamycin, avasimibe, simvastatin, Sandoz 58-035, DEUP, 
cholesteryl oleate, glyceryl trioleate, A922500, DHT, and AA were purchased from 
Sigma-Aldrich. Human LDL was obtained from Creative Laboratory Products. LPDS 
was purchased from Biomedical Technologies. The PTEN inhibitor BPV(pic) was 
purchased from Enzo Life Sciences. 
2.2.4 Label-free Spectroscopic Imaging 
Label-free spectroscopic imaging was performed on unfixed and unstained tissue 
slices (~ 20 µm) and live cells without any processing or labeling. SRL imaging was 
performed on a femtosecond SRL microscope, with the laser beating frequency tuned to 
the C-H stretching vibration band at 2845 cm-1, as described previously [248]. 
Compositional analysis of individual LDs and autofluorescent granules was performed by 
integration of high speed CARS imaging and confocal Raman spectral analysis on a 
single platform [243]. We quantify lipid metabolism profiles in two aspects, that is, LD 
amount (or LD area fraction) and CE percentage. By using ImageJ “Threshold” function, 
LDs in the cells can be selected because of their significantly higher signal intensities 
compared to other cellular compartments. Then, by using ImageJ “Analyze Particles” 
function, area fraction of LDs out of total image area can be quantified. For tissue 
specimen, the area fractions of LDs from the two different locations were averaged to 






normalized by cell number to obtain LD amount, and 50~100 cells were analyzed. The 
percentage of CE in individual LDs was quantified by using the equation, that is, Height 
ratio (the height ratio of the 702 cm-1 peak to the 1442 cm-1 peak, I702/I1442) = 0.00255 × 
CE percentage (%). The corresponding calibration curve is shown in Figure 2.2T. For 
statistical analysis, CE percentage for each specimen or cell culture was obtained by 
averaging the CE percentage of LDs in 5~10 cells, given that Raman profiles of LDs in 
different cells in the same specimen or cell culture were nearly the same (Figure 2.2R). 
Average acquisition time for a 512 x 512 pixels SRL image was 1.12 second. 
Large-area SRL imaging was performed on a motorized stage. Each large-area SRL 
image was generated by stitching 100 images of ~157 µm × 157 µm in size together. Two 
different locations were imaged for each specimen. Simultaneously, backward-detected 
two-photon fluorescence signal was collected through a 520/40 nm bandpass filter for the 
imaging of autofluorescent granules.  
The background of Raman spectrum was removed as described [243]. 5-10 
spectra of LDs or autofluorescent granules in 5-10 different cells were taken for each 
specimen. Each Raman spectrum ranged from 380 to 3100 cm-1 and was acquired in 20 
seconds. The laser (~707 nm) power at the specimen was maintained at 15 mW, and no 
cell or tissue damage was observed.  
2.2.5 Fluorescence Imaging of LDL Uptake 
DiI-LDL was made using dry film method [249]. Cells in growth medium 
containing 10% lipoprotein deficient serum with or without the indicated inhibitors (for 
2d) were incubated with DiI-LDL (20 µg/ml) for 3 hr at 37 °C and then imaged by two-






was quantified based on fluorescence intensity of DiI using ImageJ, and normalized by 
cell number. No LDL uptake was detected in cells incubated at 4 °C. 
2.2.6 Cell Viability Assay 
Cells were grown in 96-well plates (~5000 cells/well) and cultured for 1 day 
followed by indicated treatments. Cell viability was measured with the MTT colorimetric 
assay (Sigma). IC50 was obtained by fitting the data with sigmoidal dose response model. 
2.2.7 Cell Cycle Analysis 
PC-3 cells treated with 7.5 µM avasimibe for 3 days and the untreated ones were 
collected, fixed, and stained with 50 µg/ml PI at 37 °C for 30 min. The DNA content was 
measured by Cytomics FC500 flow cytometer (Beckman Coulter). Data were processed 
and analyzed by FlowJo software (Tree Star). Cell-cycle phases and frequencies of each 
phase were determined by fitting the data with Watson-Pragmatic model. 
2.2.8 Migration and Invasion Assays 
Invasion and migration assays were performed in Transwell chambers (Corning) 
with 8 µm pore-sized membranes, coated with and without Matrigel (BD Bioscience) 
respectively. One to two days before the start of the assays, cells received indicated 
treatments. At the start of the assays, cells were harvested and counted. 1×106 cells were 
seeded in the upper chamber of the transwells in 1.5 ml serum-free media. The media in 
lower chamber contain 20% FBS. Cells were allowed to migrate for 12 hr and invade for 
24 hr at 37 °C. The transwell membranes were then fixed and stained with PI. Cells that 
had not migrated or invaded through the chamber were removed with a cotton swab. The 






4 fields were independently counted from each migration or invasion chamber. An 
average of cells in 4 fields for one migration or invasion chamber represents n = 1. 
2.2.9 ESI-MS Measurement of Lipid Extraction 
Lipid extraction from cell pellets and tissues was performed according to Folch et 
al [250].  Cells with indicated treatments were collected and counted. ESI-MS analysis 
was conducted according to the protocol described previously [251]. The relative level of 
cholesteryl oleate (18:1) was normalized by cell number for comparison between control 
and avasimibe-treated cells, and was normalized by tissue weight for comparison 
between normal prostate and PCa tissues. 
2.2.10 Biochemical Measurement of Cellular Lipids 
Lipids were extracted as described above. CE, free cholesterol, and TG 
concentrations were measured according to the manufacturer’s protocol (Amplex Red 
Cholesterol kit from Molecular Probes, Serum Triglyceride Determination Kit from 
Sigma), and finally normalized by protein content that was determined by bicinchoninic 
acid assay. 
2.2.11 LC-MS Analysis of AA 
Cells cultured in 10% LPDS were pre-treated with 7.5 µM avasimibe for 2 days 
or transfected with ACAT-1 shRNA for 3 days. LDL (20 µg/ml) were then added back to 
the medium for 6 hr before the cells were collected and counted. Fatty acids were 
extracted and measured according to the methods described previously [252]. The final 







After indicated treatments, cells were lysed in AMI lysis buffer (Active Motif), 
and proteins were detected by immunoblotting with the antibodies against SREBP-1 (BD 
Pharmingen, 557036), SREBP-2 (Santa Cruz, sc-5603), p-AKT (Cell Signaling, 4060L), 
p-S6 (Cell Signaling, 2211L), LDLr (Millipore, MABS26), ACAT-1 (Santa Cruz, sc-
69836), and β-actin (Sigma, A5441). 
2.2.13 IHC 
Murine paraffin-embedded slides were deparaffinized and rehydrated. Then 
antigens were retrieved in antigen unmasking solution (Vector Laboratories) with a 2100-
Retriever (PickCell Laboratories). Samples were then incubated with the antibody against 
Ki67 (Abcam, ab16667) or subjected to TUNEL assay (Roche, 11684817910). 
2.2.14 RNA Interference 
RNA interference was employed to specifically deplete endogenous SREBP-1, 
SREBP-2, ACAT-1, and PTEN. Plasmids pLKO.1-SREBP-1 and pLKO.1-SREBP-2 
were constructed with the targeting sequences CAACCAAGACAGUGACUUCCC and 
CAACAGACGGUAAUGAUCACG.  The ACAT-1 shRNA plasmid and PTEN shRNA 
lentiviral particle were purchased from Santa Cruz (sc-29624-SH, sc-29459-V).  Plasmid 
DNA was transfected with Lipofectamine®2000 (Invitrogen 11668030) as described in 
the manufacturer’s protocols. 
2.2.15 Treatment of PCa in a Mouse Xenograft Model 
The protocol for this animal study was approved by the Purdue Animal Care and 
Use Committee. PC-3 cells (2 × 106) were mixed with an equal volume of Matrigel (BD 






nude mice (Harlan Laboratories). Treatments started 2 weeks after tumor implantation 
when the xenografts were about ~100 mm3 (day 0). Inhibitors were dissolved in DMSO, 
diluted with the solvent PBS containing 1% Tween-80, and administrated via daily 
intraperitoneal injections for 30 days at the dose of 15 mg/kg for avasimibe and Sandoz 
58-035, and at the dose of 3 mg/kg for A922500. The reason that the dosage of A922500 
is lower than that of Sandoz 58-035 and avasimibe is A922500 has substantially lower 
IC50 compared to Sandoz 58-035 or avasimibe for inhibition of the target enzyme, that is, 
IC50 of A922500 to inhibit DGAT-1 is ~7 nM vs. IC50 of Sandoz 58-035 and avasimibe 
is ~3.3 µM [253-255]. Thus, the dosages for injections were selected based on previous 
animal studies on these inhibitors [253, 256, 257]. Tumor volume, estimated from the 
formula: V=L×W2/2 (V: volume, mm3; L: length, mm; W: width, mm), was measured 
twice a week with digital calipers. Relative tumor volume = tumor volume / initial tumor 
volume (measured on day 0), for each mouse. Body weight was also measured twice a 
week. Tumors and major organs, including heart, liver, lung, kidney, and spleen, were 
harvested on day 30 and prepared for tumor weight measurement, spectroscopic imaging, 
H&E, and IHC staining. 
2.2.16 Statistical Analysis 
Results of LD area fraction and CE percentage in human prostate tissues were 
shown as mean ± SD. Other results were shown as mean ± SEM. One-way ANOVA was 
used for comparisons of LD area fraction, LD amount, and CE percentage among 
different lesion types of human PCa and different treatment conditions of cell cultures. 
All other comparisons that only include two groups in cellular and animal studies were 







2.3.1 Aberrant Accumulation of Esterified Cholesterol in Advanced Human PCa 
Revealed by Raman Spectromicroscopy 
We examined a spectrum of human prostate pathologies, including normal 
prostate from healthy donors and normal adjacent tissues from PCa patients (n = 19), 
BPH (n = 10), prostatitis (n = 3), PIN (n = 3), low-grade (Gleason grade 3, n = 12) and 
high-grade (Gleason grade 4/5, n = 12) PCa from patients who had not received hormone 
therapy, and metastases (n = 9) from patients who had failed hormone therapy. By tuning 
the laser beating frequency to be resonant with C-H stretching vibration, substantial SRL 
signals arose from the lipid-rich cell membranes and intracellular LDs, whereas weak 
SRL signals were derived from the lipid-poor cell nuclei. Morphologically, the SRL 
images provided identical information as H&E-stained slides. In normal prostate, BPH, 
PIN, and prostatitis, single layers of epithelial cells facing large lumens were identified 
by SRL imaging (Figures 2.1A, 2.2). In cancerous specimens, the SRL signals revealed 
small glandular structures in low-grade PCa (Figure 2.1B) and cell clusters or sheets 
without any glandular structures in high-grade PCa (Figure 2.1C). SRL image of 
metastasis is shown in Figure 2.1D. All diagnoses were confirmed by pathologic 
assessment of the neighboring slices stained with H&E (Figures 2.1E-H, 2.2). By 
combining SRL with two-photon fluorescence on the same microscope, we found that the 
intracellular granules present in normal prostate expressed both SRL and fluorescence 








Figure 2.1 Aberrant CE accumulation in human PCa tissues. (A-D) Large-area 
SRL images and benign prostate, low-grade PCa (Gleason grade 3), high-
grade PCa (Gleason grade 4), and metastatic PCa (liver), respectively. (E-H) 
Corresponding hematoxylin and eosin (H&E) staining of adjacent slices. 
Scalar bar, 100 µm. (I-L) High magnification SRL and two-photon 
fluorescence images of the lesions shown in (A-D) (grey: SRL, green: two-
photon fluorescence). Autofluorescent granules and LDs indicated by red 
arrows. Scalar bar, 20 µm. (M) LD area fraction in 58 specimens: normal 
prostate (n = 19), low-grade PCa (n = 9), high-grade PCa (n = 11), and 
metastatic PCa (n = 9). Mean of LD area fraction indicated by red line. n.s. 
means not significant. (N) Raman spectra of autofluorescent granules in 
normal prostate, LDs in PCa, and pure cholesteryl oleate. Spectral intensity 
was normalized by CH2 bending band at 1442 cm
-1. Black arrows indicate the 
bands of cholesterol rings at 702 cm-1. (O) CE molar percentage in LDs of 
low-grade PCa (n = 9), high-grade PCa (n = 11), and metastatic PCa (n = 9). 






These autofluorescent granules were consistently seen in all 19 normal prostates, 10 BPH, 
and 3 PIN lesions (Table 2.1, Figure 2.2G-I), and were determined to be lipofuscin 
according to previous reports on pigments in benign prostate [258]. No LDs or 
autofluorescent granules were observed in prostatitis specimens (Figure 2.2J-L). In 
contrast, with the exception of 4 borderline PCa cases, the 20 primary PCa and all 9 
metastases contained significant amount of LDs but no autofluorescent granules (Figure 
2.1J-L, Table 2.1). Interestingly, we have found in a spontaneous mouse model of PCa 
(TRAMP) that whereas normal mouse prostate only contains autofluorescent granules, 
cancerous mouse prostate show accumulation of neutral LDs (Figure 2.2N-O). By large-
area mapping and quantitation, the area fraction of LDs in human PCa tissues was found 
to be 0.78 ± 0.65% for low-grade PCa, 3.93 ± 1.74% for high-grade PCa, and 2.76 ± 1.19% 
for metastatic PCa (Figure 2.1M, Table 2.1). The high-grade PCa has significantly higher 
LD area fraction by ~5 folds (p = 8.9E-5) compared to low-grade PCa. 
To evaluate the lipid composition, we performed confocal Raman spectral 
analysis of individual autofluorescent granules or LDs accumulated in each lesion type. 







Figure 2.2 CE accumulation in normal prostate, BPH, PIN, or prostatitis. (A-I) 
Label-free SRL and two-photon fluorescence imaging of normal prostate, 
BPH, and PIN. (J-L) Label-free SRL and two-photon fluorescence imaging of 
prostatitis tissue. Grey: SRL; Green: two-photon fluorescence. Scalar bar: 100 
µm for large-area images, 20 µm for high-magnification images. (M) 
Normalized two-photon fluorescence spectrum of autofluorescent granule in 
normal prostate. (N-O) SRL and two-photon fluorescence images of normal 
and cancerous mouse prostate tissues in a spontaneous PCa TRAMP model. 
Scalar bar, 20 µm. (P) Raman spectra of different autofluorescent granules in 
one normal prostate tissue. (Q) Raman spectra of autofluorescent granules in 
BPH and PIN lesion. (R) Raman spectra of LDs in different cells in one PCa 
specimen. (S) Raman spectra of CE-TG emulsions with eight different CE:TG 
molar ratios, ranging from 0:10 to 10:0. (T) Calibration curve for 
quantification of CE percentage out of total neutral lipid. (U) Mass spectra of 







(Gleason grade 3), high-grade PCa (Gleason grade 4), metastatic PCa (liver), and pure 
cholesteryl oleate. The autofluorescent granules seen in normal prostate consistently 
showed readily detectable bands for lipid (1200-1800 cm-1), phenylalanine (~1000 cm-1), 
and prominent CH3 stretching (~2930 cm
-1), but lacked the characteristic C=O ester 
stretching band at 1742 cm-1 (Figure 2.2P). These data suggest that the autofluorescent 
granules are primarily composed of unesterified lipids and proteins. Similar Raman 
profiles were seen in both BPH and PIN lesion (Figure 2.2Q). Importantly, the spectra of 
intracellular LDs in low-grade, high-grade, and metastatic PCa (Figure 2.1N) were 
distinctly different from those collected in normal prostate, BPH, and PIN lesions, but 
nearly identical to the spectrum of pure cholesteryl oleate, with characteristic bands at 
428, 538, 614 and 702 cm-1 for cholesterol ring and for ester bond at 1742 cm-1 [259]. 
Spectra taken from various LDs in the same cancer specimen are nearly identical (Figure 
2.2R), which allowed quantitation of CE percentage. Given that neutral lipids in LDs are 
predominantly TG and CE [81], we recorded Raman spectra of mixed emulsions 
containing  cholesteryl oleate and glyceryl trioleate (Figure 2.2S). We found that the 
height ratio between the most prominent cholesterol band at 702 cm-1 and the CH2 
bending band at 1442 cm-1 was linearly proportional to the molar percentage of CE 
present in the total lipids (Figure 2.2T). Based on this calibration curve, we found that 
LDs were ubiquitously rich in CE independent of the types of PCa, specifically 90.2 ± 
9.1 % for low-grade, 90.6 ± 4.9 % for high-grade, and 70.3 ± 18.5 % for metastasis 
(Figure 2.1O, Table 2.1). Electrospray ionization mass spectrometry analysis of extracted 






Table 2.1 Detection of LDs and autofluorescent granules in prostate specimens from 













Mean ± SD (%) 
Normal b 
(n = 19) 
Positive ND c 
   
BPH 
(n = 10) 
Positive ND 
   
Prostatitis 
(n = 3) Negative 
ND 
   
PIN 
(n = 3) 
Positive ND 
   
Low-grade PCa 
(Gleason 3, 
n = 9) d 
Negative 
0.155 
0.78 ± 0.65 
 
69.9 












n = 11) e 
Negative 
3.974 
3.93 ± 1.74 
84.0 












(n = 9) Negative 
1.431 
2.76 ± 1.19 
89.0 










a SD = standard deviation 
b Normal prostate tissues were collected from healthy donors (n = 3) and PCa patients (n = 16). 
c ND = not detectable 
d Borderline cases (Gleason 3): one tissue specimen does not have any lipid accumulation; two tissue 
specimens only contain autofluorescent granules but not LDs. 
e Borderline case (Gleason 4/5): one tissue specimen only contain autofluorescent granules but not LDs. 
f Metastases: liver (n = 2), lymph node (n = 3), rib (n = 1), lung (n = 1), adrenal (n = 1), and abdominal soft 






prostate, and further showed that cholesteryl oleate was the dominant species (Figure 
2.2U).  
 
2.3.2 CE Accumulation in PCa Is Not Correlated with Androgen Signaling 
Because the AR remains transcriptionally active in castration-resistant PCa [185], 
and cholesterol is the precursor of the entire androgen synthesis cascade, we first 
speculated that CE accumulation is associated with androgen signaling in PCa. To test 
this hypothesis, we examined non-transformed human prostate epithelium and a panel of 
human PCa cells (Figure 2.3A, B, Table 2.2). As shown in Figure 2.3C, the LDs in non-
transformed prostate RWPE1 cells showed a low CE level (< 20%), which remained low 
upon addition of 10% FBS into the culture medium (Figure 2.4A). For AR-negative 
cancer cells, we examined bone metastasis-derived PC-3 and brain metastasis-derived 
Table 2.2 Origin, AR expression, androgen dependence, and PTEN status in various 
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Figure 2.3 CE accumulation is not correlated with androgen signaling. (A) 
SRL images of various types of cells, including RWPE1, LNCaP-LP, LNCaP-
HP, PC-3, DU145, and C4-2. LDs indicated by green arrows. (B) Raman 
spectra of LDs in different cell lines shown in (A). Spectral intensity was 
normalized by the peak at 1442 cm-1. Black arrows indicate the bands of 
cholesterol rings at 702 cm-1. (C) Quantitation of LD amount and CE 
percentage. LD amount was normalized by the RWPE1 group. Error bars 
represent SEM. n > 5. **: p < 0.005, ***: p < 0.0005. (D) Nuclear 
translocation of AR in LNCaP-LP and LNCaP-HP cells. Blue: DAPI, Red: 








Figure 2.4 CE measurements of RWPE1 and 22Rv-1 cells in various culture 
conditions. (A) CE measurement of RWPE1 cells cultured in regular serum-
free medium and the medium supplemented with 10% FBS. (B) SRL images 
of 22Rv-1 cells treated with different concentrations of dihydrotestosterone 
(DHT). DHT was diluted in phenol-red free RPMI + 10% charcoal-stripped 
serum, 4 days incubation. Scalar bar, 10 µm. 
 
DU145, and found that CE level was high in PC-3 (> 90%) but low in DU145 (< 20%). 
For AR-positive cancer cells, we used low passage LNCaP (LNCaP-LP) and high 
passage LNCaP (LNCaP-HP) as models for PCa progression [244]. The CE level was 
high (> 80%) in the androgen-independent LNCaP-HP, but low (< 20%) in the androgen-
dependent LNCaP-LP. Notably, LD accumulation in LNCaP-LP was reported and 
attributed to the upregulation of FASN [87, 88]. Our data showed a dramatic increase of 
CE levels in LDs during progression of LNCaP cells from androgen-dependent to 
androgen-independent stage. Meanwhile, a key step of androgen signaling, nuclear 
translocation of AR, was seen in CE-poor LNCaP-LP cells but not in CE-rich LNCaP-HP 
cells (Figure 2.3D). Finally, we found, in AR-positive and androgen-independent C4-2 
and 22Rv-1 cells, that CE level was low (< 20%) in C4-2 cells (Figure 2.3C) and LD 






2.4B). These data collectively imply that CE accumulation may be linked to a pathway 
that is independent of androgen signaling. 
 
2.3.3 CE Accumulation Is Driven by Loss of PTEN and Consequent Upregulation of 
PI3K/AKT/mTOR/SREBP Pathway 
The finding that CE accumulated in PC-3 cells (PTEN-deleted) but not in DU145 
cells (PTEN-normal) then triggered us to ask whether CE accumulation resulted from 
loss of tumor suppressor PTEN, which is known to activate a pathway bypassing the AR 
[185]. Loss of PTEN has been widely observed in both localized and metastatic PCa and 
is correlated with high Gleason grade [260]. With loss of PTEN, PI3K signaling is 
hyperactivated, which, in turn, leads to AKT activation. The upregulated PI3K/AKT 
pathway has been implicated in carcinogenesis and metastasis of PCa [261, 262]. To 
determine the extent to which PTEN is involved, we first reintroduced wild-type PTEN 
into PC-3 cells and found CE levels to be significantly reduced (Figure 2.5A). Then, we 
knockdowned PTEN in DU145 cells using shRNA and found a significant increase in CE 
levels (Figure 2.5B). We further inhibited PTEN in DU145 cells using BPV (a PTEN 
inhibitor) and also found a significant increase in CE levels (Figure 2.6A). To determine 
the potential role of the PI3K/AKT/mTOR pathway in regulating CE accumulation, we 
treated PC-3 cells (the CE-rich cell line) with LY294002 (a selective PI3K inhibitor), 
MK2206 (a selective AKT inhibitor), and rapamycin (a selective mTOR inhibitor), 
respectively.  Although total LD amounts were not markedly reduced upon inhibitor 








Figure 2.5 CE accumulation is induced by loss of PTEN and activation of 
PI3K/AKT pathway. (A) CE levels in PC-3 cells transfected with PTENWT 
plasmid for 3 days. Raman spectra of LDs in control and PTEN-overexpressed 
cells are shown on the left. The band of cholesterol rings at 702 cm-1 nearly 
disappeared after the treatment, as indicated by the arrows. Quantitation of CE 
percentage and LD amount is shown on the right. n > 5. (B) CE measurement 
of DU145 cells transfected with PTEN shRNA lentiviral particle for 3 days. 
Raman spectra of LDs in control and transfected cells are shown on the left. 
The band of cholesterol rings at 702 cm-1 significantly increased after the 
treatment, as indicated by the arrows. Quantitation of CE percentage and LD 
amount is shown on the right. n > 5. (C) SRL images of cells treated with 
DMSO as control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), rapamycin 
(100 nM, 2d), and SREBP-1 and -2 siRNA (2d transfection). LDs indicated by 
green arrows. Scalar bar, 10 µm. (D) Quantitation of CE percentage and LD 
amount in cells shown in (C). n > 5. (E) Immunoblot of the antibodies against 
p-AKT, p-S6, SREBP-1 and -2, and β-Actin in cells treated with DMSO as 
control (Ctl), LY294002 (LY), MY2206 (MK), and rapamycin (Rapa). P: 
precursor form, C: cleaved form. The expression levels of p-AKT and p-S6 
were reduced after inhibitor treatments as expected. Error bars represent SEM. 







Figure 2.6 CE accumulation is not correlated with androgen signaling, but 
rather induced by loss of PTEN and activation of PI3K/AKT pathway. (A) CE 
measurement of DU145 cell treated with a potent inhibitor of PTEN, BPV(pic) 
(10 µM) for 3 days. Raman spectra of LDs in control and transfected cells are 
shown on the upper row. The band of cholesterol rings at 702 cm-1 
significantly increased after the treatment, as indicated by the arrows. 
Quantitation of CE percentage and LD amount is shown on the bottom row. n 
> 5. (B) Raman spectra of LDs in PC-3 cells undergone various treatments 
including LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), rapamycin (100 nM, 
2d), SREBP-1 and -2 siRNA (2d transfection). The bands of cholesterol rings 
at 702 cm-1 were significantly reduced after the treatments, as indicated by the 
arrows. (C) LD amount and CE percentage of LNCaP-HP cells treated with 
DMSO as control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), and 
rapamycin (100 nM, 2d). (D) Immunofluorescence images of DAPI (blue) and 
AR (red) in LNCaP-LP cells and LNCaP-HP cells treated with DMSO as 
control, LY294002, MK2206, and rapamycin. (E) Immunoblot of the 
antibodies against PTEN, SREBP-1 or -2 (precursor forms), and β-Actin in 






as shown by spectral analysis (Figure 2.6C). We have also inhibited 
PI3K/AKT/mTOR pathway in LNCaP-HP cells and found that both LD amount and 
CE levels were significantly reduced upon inhibitor treatments (Figure 2.6D). In the 
meanwhile, AR translocation was still not detected in the LNCaP-HP cells upon 
inhibition of PI3K/AKT/mTOR pathway (Figure 2.6E), which further supports that 
CE accumulation is not correlated with androgen signaling. 
It is known that AKT mediates the activation of mTOR complex 1 that plays a 
critical role in regulating the function of SREBPs [69]. The SREBPs are transcription 
factors that function to control lipid and cholesterol homeostasis by sensing cellular 
cholesterol [70]. Increased activation of SREBPs was found in advanced PCa [183]. 
Using RNA interference, we found that knockdown of both SREBP-1 and -2 led to 
significant reduced CE levels in PC-3 cells without affecting LD amount, and knockdown 
of SREBP-1 resulted in a stronger effect than knockdown of SREBP-2 (Figures 2.5C, D, 
and 2.6C). Using immunoblotting, we further found that inhibition of the 
PI3K/AKT/mTOR pathway significantly suppressed both the level and cleavage of 
SREBP-1 in PC-3 cells (Figure 2.5E), indicating that CE accumulation is closely related 
to the activity of SREBP-1 isoforms. These results collectively suggest that CE 
accumulation is regulated by the PI3K/AKT/mTOR/SREBP pathway.  
 
2.3.4 CE Accumulation in PCa cells Arises from Enhanced Uptake of Exogenous LDL 
Because cholesterol can be either de novo synthesized via the mevalonate 








Figure 2.7 CE accumulation arises from enhanced uptake of exogenous LDL 
and involves cholesterol esterification by ACAT-1.  (A) LD amount and CE 
percentage in PC-3 cells treated with or without simvastatin (10 µM, 1d), n > 
5. (B) SRL images and quantitation of LD amount in PC-3 cells treated with 
LPDS (10%, 1d) and subsequent LDL re-addition (45 µg/ml, 1d), n = 6. LDs 
indicated by green arrows. (C) Quantitation and representative images of DiI-
LDL uptake by PC-3 cells treated with DMSO as control, LY294002, and 
rapamycin (grey: SRL, green: two-photon fluorescence), n = 5. DiI-LDL 
intensity was normalized by the control group. (D) Raman spectra of LDs and 
quantitation of LD amount and CE percentage in PC-3 cells treated with 
avasimibe (7.5 µM, 1d) and ACAT-1 shRNA (3d transfection). n > 5. Spectral 
intensity was normalized by the peak at 1442 cm-1. The bands of cholesterol 
rings at 702 cm-1 nearly disappeared after the treatments, as indicated by the 
arrows. LD amount was normalized by the control group in (B, D). (E) Mass 
spectra of lipids extracted from control and avasimibe-treated PC-3 cells (7.5 
μM, 2d). The m/z 668 peak stands for cholesteryl oleate (CE 18:1). Error bars 
represent SEM. **: p < 0.005, ***: p < 0.0005. Scalar bar, 10 µm. LPDS: 






cholesterol used for CE accumulation. We first treated PC-3 cells with simvastatin, an 
inhibitor of HMGCR, the rate-limiting enzyme of the mevalonate pathway. As shown in 
Figure 2.7A, simvastatin neither decreased LD amount nor significantly reduced CE 
levels. In contrast, after treating cells with lipoprotein-deficient serum, LDs nearly 
disappeared in CE-rich PC-3 cells (Figure 2.7B), but remained the same amount in CE-
poor cells, including LNCaP-LP, DU145, and C4-2 (Figure 2.8A-B). Re-addition of LDL 
into the lipoprotein-deficient medium restored LDs in PC-3 cells (Figure 2.7B) and the 
CE level in these LDs was 93.6 ± 5.5 %. By treating cells with DiI-LDL, it was found 
that LDL uptake was the most prominent in the CE-rich PC-3 cells compared to CE-poor 
PCa cells (Figure 2.8C-D). Moreover, inhibition of the PI3K/AKT/mTOR pathway 
significantly reduced expression levels of LDLr (Figure 2.8E) and blocked the uptake of 
DiI-LDL in PC-3 cells (Figure 2.7C). Knockdown of SREPB-1 using siRNA also 
reduced the LDL uptake in PC-3 cells (Figure 2.8F). These results collectively indicate 
that exogenous LDL is the primary source for CE accumulation. 
 
2.3.5 CE Accumulation in PCa Cells Requires Cholesterol Esterification by ACAT-1 
LDL is known to enter a cell via LDLr and traffic to the late endosome and 
lysosome to be hydrolyzed to FFAs and free cholesterol. The excess free cholesterol 
together with the fatty acyl CoA substrate is then converted to CE by ACAT and stored in 
LDs [170]. Thus, we treated cells separately with avasimibe and Sandoz 58-035, two 
different ACAT inhibitors. Both inhibitors effectively suppressed CE accumulation in 







Figure 2.8 LDs in CE-poor cells do not arise from exogenous LDL, whereas 
CE accumulation in CE-rich cells arises from enhanced uptake of exogenous 
LDL. (A-B) Representative SRL images and quantitation of LD amount of 
various CE-poor cancer cells, including LNCaP-LP, DU145, and C4-2, before 
and after LPDS treatment (1d). LD amounts in cells before treatments were 
normalized for each cell line. (C-D) Representative images and quantitation of 
DiI-LDL uptake in various cell lines, including RWPE1, LNCaP-LP, LNCaP-
HP, PC-3, DU145, and C4-2. DiI-LDL treatment: 20 µg/ml for 3 hr. Grey: 
SRL; Green: two-photon fluorescence. (E) Immunoblot of the antibodies 
against LDLr, ACAT-1, and β-Actin in PC-3 cells treated with DMSO as 
control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), and rapamycin (100 
nM, 2d). (F) Quantitation of DiI-LDL uptake in PC-3 cells transfected with 
SREBP-1 siRNA. (G) SRL images and Raman spectra of LDs in PC-3 cells 
with and without Sandoz 58-035 treatment (10 µM, 1d). The bands of 
cholesterol rings at 702 cm-1 nearly disappeared after the treatments, as 
indicated by the arrows. (H) Effect of avasimibe treatment (7.5 μM, 2d) on 
fraction of CE out of total cholesterol in PC-3 cells, measured by biochemical 
assay. (I) Relative levels of cholesteryl oleate (CE 18:1) in control and 
avasimibe-treated PC-3 cells (7.5 μM, 2d), measured by mass spectrometry 
and normalized by cell number (n = 3). (J) Immunoblot of the antibodies 
against ACAT-1 and β-Actin in control and ACAT-1 siRNA-transfected PC-3 
cells. Scalar bar = 10 µm. Error bars represent SEM. *: p < 0.05. **: p < 0.005, 






The significant reduction of CE accumulation upon avasimibe treatment was verified by 
biochemical assay (Figure 2.8H) and mass spectrometry of extracted lipids from PC-3 
cells (Figures 2.7E, 2.8I). The mass data further showed that cholesteryl oleate was the 
dominant species present. Because avasimibe inhibits both ACAT-1 and -2 isoforms, we 
specifically knocked down ACAT-1 using shRNA and found significant reduction of the 
CE level in PC-3 cells (Figures 2.7D, 2.8J). In addition, inhibition of PI3K/AKT/mTOR 
pathway significantly reduced expression levels of ACAT-1 (Figure 2.8E). These results 
collectively confirm the involvement of ACAT-1 in CE storage in PCa cells. 
 
2.3.6 Pharmacological Depletion of CE Storage Impairs PCa Aggressiveness 
Because CE accumulation was found in PCa but was not detectable in normal 
prostate, we evaluated how cell viability could be affected by regulating CE levels with 
ACAT inhibitors. As shown in Figure 2.9A and Figure 2.10A, treatments of two ACAT 
inhibitors, avasimibe and Sandoz 58-035, significantly reduced viability of PC-3 cells, 
with IC50 value of 7.3 µM and 17.2 µM, respectively.  The inhibitory effect of avasimibe 
on the growth of PC-3 and LNCaP-HP cells was considerably greater than that in CE-
poor PCa cells, including LNCaP-LP, DU145, and C4-2 (Figure 2.10B), with IC50 value 
of 9.6 µM in LNCaP-HP cells (Figure 2.10C). Results from flow cytometry analysis 
(Figure 2.9B) revealed that exposure of PC-3 cells to avasimibe resulted in both cell 
cycle arrest and apoptosis, i.e. the G2/M phase population was ~2 times smaller whereas 
the sub-G1 population was ~3 times larger in avasimibe-treated group compared to 
control group. To confirm the effect of ACAT inhibition on cell viability, we treated PC-







Figure 2.9 CE depletion impairs human PCa aggressiveness. (A) IC50 curves 
of avasimibe and Sandoz 58-035 treatments on PC-3 cells. n = 6 per group. (B) 
Flow cytometry analysis of cell cycle in control and avasimibe-treated PC-3 
cells (n = 3). (C, D) Quantitation of migrated and invaded PC-3 cells that were 
pretreated with DMSO as control, avasimibe (5 µM), Sandoz 58-035 (SaH, 10 
µM), and ACAT-1 shRNA for 2d (n = 3). And quantitation of migrated and 
invaded PTEN knockdown (PTEN-KD) DU145 cells that were pretreated 
with DMSO as control and avasimibe (5 µM) for 1d (n = 3). (E) Relative 
tumor volume of PC-3 xenograft (n = 9). Relative tumor volume = tumor 
volume / initial tumor volume (day 0) for each mouse. Representative tumors 
harvested on day 30 are shown in the inset. Scalar bar, 1 cm.  (F) Weight of 
tumor tissues harvested from mice (n = 8). (G) Body weight of mice over 30-
day treatments (n = 9). (H) CE percentage of tumor tissues harvested from 
mice (n = 5). (I) Representative images of H&E staining, IHC of Ki67, and 
TUNEL labeling (blue: DAPI, cyan: TUNEL-positive) of vehicle and 
avasimibe groups. Scalar bar, 100 µm. (J) Percentage of Ki67 and TUNEL 
positive cells in vehicle and avasimibe groups (n = 5). Error bars represent 






which catalyzes the terminal step of TG formation, and found that DGAT inhibition did 
not affect cell viability until high doses (Figure 2.10C). We also showed that specific 
knockdown of ACAT-1 using shRNA significantly reduced viability of PC-3 cells 
(Figure 2.10D). Moreover, ACAT inhibition by avasimibe significantly suppressed 
viability of PTEN knockdown DU145 cells (Figure 2.10D). To evaluate whether CE 
depletion affects tumor aggressiveness, we conducted standard transwell assays and 
found that both migration and invasion capabilities of PC-3 cell were markedly 
suppressed upon ACAT inhibition by avasimibe, Sandoz 58-035, and ACAT-1 shRNA 
(Figures 2.9C, D, 2.10E). And also in PTEN knockdown DU145 cells, ACAT inhibition 
by avasimibe significantly suppressed cell migration and invasion capabilities (Figure 
2.9C, D). In contrast, DGAT inhibition slightly increased PC-3 cell migration and 
invasion (Figure 2.10F). Notably, negligible toxic effects on non-transformed prostate 
RWPE1 cells were found at the same dose of avasimibe treatments (Figure 2.10B).  
To test the potential of using ACAT inhibition to treat advanced PCa in vivo, we 
administered two ACAT inhibitors, avasimibe and Sandoz 58-035 (15 mg/kg, via 
intraperitoneal injection), to athymic nude mice bearing PC-3 xenografts. Daily treatment 
of mice with ACAT inhibitors inhibited the growth of PC-3 tumors by ~2 fold (Figures 
2.9E, 2.10G), and significantly reduced weight of tumor tissues (Figures 2.9F, 2.10H). 
Importantly, ACAT inhibitors did not cause general toxicity to animals, as indicated by 
no change observed in animal behavior or body weight (Figures 2.9G, 2.10I). 
Pathological review of sections of heart, kidney, liver, lung, and spleen harvested from 
mice receiving avasimibe showed no detectable signs of toxicity (Figure 2.10J). 







Figure 2.10 CE depletion using various ACAT inhibitors or RNA interference 
suppresses PCa viability and growth in vivo with negligible toxicity. (A) 
Proliferation curves of control and avasimibe-treated PC-3 cells (n = 6). (B) 
Viability of various cell lines, including RWPE1, LNCaP-LP, LNCaP-HP, 
PC-3, DU145, and C4-2, treated with avasimibe. n = 6 per group. (C) IC50 
curves of avasimibe treatment on LNCaP-HP cells and DGAT-1 inhibitor 
A922500 treatment on PC-3 cells. n = 6 per group. (D) Viability of PC-3 cells 
transfected with ACAT-1 shRNA for 3 days. And viability of PTEN 
knockdown (PTEN-KD) DU145 cells treated with avasimibe (7.5 µM) for 2 
days. (E) Images of migration and invasion of PC-3 cells pre-treated with 
avasimibe (5 µM, 2d). Red: PI staining. Scalar bar, 50 µm. (F) Quantitation of 
migrated and invaded PC-3 cells pre-treated with DGAT-1 inhibitor A922500 
(10 µM, 2d), n = 3. (G) Relative tumor volume of PC-3 xenograft (n = 8). (H) 
Weight of tumor tissues (n = 8). (I) Body weight of mice (n = 8). (J) H&E 
staining of tissue sections. Scalar bar, 100 µm. (K) Raman spectra of PC-3 








Figure 2.11 CE depletion reduces human PCa cell proliferation by limiting 
uptake of essential fatty acids. (A) Free cholesterol level in control (Ctl: 
DMSO as control) and avasimibe (Ava)-treated PC-3 cells (n = 3). (B) 
Immunoblot of the antibodies against SREBP-1 and -2, LDLr, p-AKT, and β-
Actin in ACAT-1 knockdown PC-3 cells. P: precursor form, C: cleaved form. 
(C) Quantitation and representative images and of DiI-LDL uptake in control 
and avasimibe-treated PC-3 cells (n = 5). Grey: SRL; Green: two-photon 
fluorescence. Scalar bar, 10 µm. DiI-LDL intensity was normalized by the 
control group. (D) AA levels in control and avasimibe-treated PC-3 cells (n = 
3). (E) PC-3 cell viability upon AA treatments. (F) PC-3 cell viability upon 
AA and/or avasimibe treatments. Viability was measured by MTT assay. The 
absorbance value measured for control group was used for normalization. 
Comparisons were made between control and treated groups (n = 6 per group). 
Error bars represent SEM. *: p < 0.05, ***: p < 0.0005. 
 
in avasimibe-treated tumors compared to vehicle-treated ones, even though LD area 
fraction was not affected (Figures 2.9H and 2.10K), indicating that ACAT inhibitor 






proliferation (Ki67) and apoptosis (TUNEL) showed that ACAT inhibitor avasimibe 
significantly reduced tumor proliferation by ~70% and increased apoptosis by ~2 fold 
(Figure 2.9I, J). 
 
2.3.7 CE Depletion Impairs PCa Growth by Limiting Uptake of Essential Fatty Acids 
We first suspected that CE storage might act as a pool of fatty acid and 
cholesterol which can be released from LDs for cancer cell proliferation. The result that 
inhibition of CE hydrolysis using diethylumbelliferyl phosphate, a selective cholesterol 
esterase inhibitor, slightly enhanced PC-3 cell growth (Figure 2.12A) excluded such 
possibility. We then asked whether CE depletion suppresses PCa proliferation by 
downregulation of the upstream pathways including LDL uptake. We notice that LDL is 
the primary carrier of essential PUFAs, including AA [263]. Inside cells, AA is released 
from LDL and converted to a range of eicosanoids that have been implicated in various 
pathological processes, including inflammation and cancer [77]. Because cholesterol 
esterification is known to play a vital role in maintaining intracellular cholesterol 
homeostasis [170], we hypothesized that abrogating ACAT activity can inhibit PCa 
growth by elevating free cholesterol levels, downregulating expression levels of SREBP 
and LDLr, and consequently reducing the uptake of LDL. To test this hypothesis, we 
measured free cholesterol levels in PC-3 cells with a biochemical assay and found that 
avasimibe treatment significantly increased the free cholesterol levels (Figure 2.11A). 
Immunoblotting measurement showed that ACAT inhibition by specific knockdown of 
ACAT-1 using shRNA and the two ACAT inhibitors (avasimibe and Sandoz 58-035) 







Figure 2.12 Mechanistic studies about the effects of ACAT-1 inhibition on 
intracellular cholesterol homeostasis. (A) Viability of PC-3 cells treated with 
different concentrations of CE hydrolase inhibitor, diethylumbelliferyl 
phosphate (DEUP), for 3 days. (B) Immunoblot of the antibodies against 
SREBP-1, -2, LDLr, p-AKT, and β-Actin in PC-3 cells treated with avasimibe 
(7.5 µM, 3d) and Sandoz 58-035 (SaH, 10 µM, 3d). P: precursor form, C: 
cleaved form. (C) AA levels in control and avasimibe-treated LNCaP-HP cells 
(n = 3). (D) PC-3 cell viability upon LDL treatments. Viability was measured 
by MTT assay. The absorbance value measured for control group was used for 
normalization. Comparisons were made between control and treated groups (n 
> 6 per group). Error bars represent SEM. *: p < 0.05, **: p < 0.005, ***: p < 
0.0005. 
 
SREBP-1, and LDLr (Figures 2.11B, 2.12B). We further monitored cellular uptake of 
DiI-LDL upon ACAT inhibitor treatment, and found that avasimibe treatment resulted in 
reduced LDL uptake by ~10 fold (Figure 2.11C). Further, liquid chromatography-mass 






avasimibe and shRNA significantly reduced the level of AA in PC-3 cells (Figure 2.11D), 
and avasimibe also significantly reduced AA levels in LNCaP-HP cells (Figure 2.12C). 
As shown elsewhere [264, 265] and confirmed herein, LDL and AA separately promoted 
the growth of PC-3 cells in a dose-dependent manner (Figure 2.11E, 2.12D). AA was also 
shown to rescue the inhibitory effect of ACAT inhibitor avasimibe on cancer cell 
viability (Figure 2.11F). Moreover, expression levels of p-AKT were significantly 
reduced upon ACAT-1 inhibition in PC-3 cells (Figures 2.11B, 2.12B). This might be 
caused by reduced levels of AA, which has been shown to activate PI3K/AKT signaling 
in PCa [266]. These data collectively provide evidence that ACAT inhibition might have 
hindered proliferation of CE-rich PCa cells by limiting the uptake of a critical 
proliferative factor, AA, via downregulation of LDLr. The molecular basis for CE 




Through integrated analyses of PCa clinical samples, cell lines, and mouse 
xenograft model, we have revealed a novel role of CE, a lipid metabolite, in human PCa 
progression. CE accumulation is known to be a hallmark of atherosclerosis and hormone-
producing organ [81, 267], however its exact role in cancer progression remains elusive. 
In this study, prominent CE accumulation that only occurs in advanced PCa is shown to 
be a consequence of the loss of tumor suppressor PTEN and subsequent activation of 
PI3K/AKT/mTOR pathway. Blockage of CE accumulation significantly impairs PCa 








Figure 2.13 Molecular pathways underlying accumulation of CE in advanced 
human PCa and suppression of cancer proliferation upon CE depletion. The 
schematic shows that loss of tumor suppressor PTEN activates 
PI3K/AKT/mTOR pathway, which in turn upregulates SREBP and LDLr. 
LDL is then hydrolyzed to FFAs and free cholesterol (FC) in lysosome. The 
excess FC together with the fatty acyl CoA substrate is converted to CE by 
ACAT-1 and stored in LDs. LDL also serves as an important carrier of ω-6 
PUFA, such as AA, which promotes cell proliferation and tumor growth. The 
red arrows depict the consequences of CE depletion. Depletion of CE storage 
by specific ACAT-1 knockdown using RNA interference or ACAT inhibitors 
disturbs cancer cell cholesterol homeostasis by elevating FC levels and 
consequently downregulating expression levels of SREBP and LDLr. 
Subsequently reduced uptake of ω-6 PUFA from LDL suppresses cancer 
proliferation. 
 
current understanding of the role of cholesterol in cancer and also open new opportunities 
for diagnosis and treatment of aggressive PCa.  
First, our study contributes to the understanding of metabolic pathways that drive 
PCa progression. Increasing evidence supports that androgen signaling pathways remain 
active throughout every stage of PCa progression [185]. However, expression levels of 






observations suggest that PCa cells may also depend on other compensatory signaling 
pathways to survival and grow. One of the most important pathways that bypass AR is 
the PI3K/AKT/mTOR pathway, which is negatively regulated by the tumor suppressor 
PTEN. PTEN has been identified as one of the most commonly lost or mutated tumor 
suppressor genes in human cancers [269].  In particular, nearly 70% of advanced PCa 
exhibit loss of PTEN or consequent activation of the PI3K/AKT pathway [270], which 
leads to enhanced cell survival, proliferation, migration, invasion, metastasis, and 
castration-resistant growth as well [261, 270, 271]. Our results, as illustrated in Figure 
2.13, show that PTEN loss induces CE accumulation by activating the PI3K/AKT/mTOR 
pathway and subsequently upregulating the expression levels of SREBP and LDLr. This 
finding elucidates the mechanism by which tumor suppressor PTEN regulates metabolic 
pathways to meet the increased demand of aggressive PCa cell for LDL cholesterol 
uptake. Our study further showed that such enhanced LDL uptake is linked to AA, a 
proliferation factor of PCa [264, 265].  
Whereas alterations to metabolism of glucose, amino acids, and fatty acids have 
been extensively studied [8], cholesterol metabolism in cancer is a relatively understudied 
field [21]. Inside cells, cholesterol is an essential molecule that plays important roles in 
the maintenance of membrane structure, signal transduction, and provision of precursor 
to hormone synthesis [93]. As early as 1942, increased level of free cholesterol in the 
adenoma of enlarged prostates was reported by analysis of tissue homogenates [272]. 
More recently, immunohistochemical staining of PCa bone metastases showed intense 
staining of the LDLr, which supports the important role of LDL uptake in PCa 






obtain sufficient cholesterol and in the meanwhile maintain intracellular cholesterol 
homeostasis remain poorly understood. Our imaging study of human tissues identified a 
possible culprit, that is, accumulation of esterified cholesterol in LDs of advanced PCa 
cells. Advanced PCa cells take advantage of the esterified form not only to avoid toxicity 
of excess cholesterol [170], but also to keep free cholesterol at relatively low level so that 
SREBP, which controls cholesterol biogenesis, is always active. This mechanism 
explains why PCa cells could maintain high expression levels of SREBP and LDLr even 
in the presence of exogenous cholesterol [175].  
We note that statin use has been linked with a decreased risk of advanced PCa 
[273], and its benefits against PCa were found to be based on systemic cholesterol-
lowering effect rather than direct effect on de novo cholesterol synthesis [274]. In 
accordance, our cellular studies reveal that cholesterol stored in the LDs of advanced PCa 
cells is not synthesized de novo, but rather derived from enhanced uptake of exogenous 
LDL. Using mass spectrometry, we find that cholesteryl oleate is the dominant species of 
CE inside the LDs. This result suggests that LDL with cholesteryl linoleate as the 
dominant form is hydrolyzed into free cholesterol and then re-esterified to CE by ACAT-
1. Together, our finding offers a biological foundation that supports the beneficial effect 
of cholesterol-lowering drugs.  
Second, our study opens a possibility of distinguishing the aggressive forms of 
PCa from the indolent ones that can be left without treatment. Since the introduction of 
prostate specific antigen screening, PCa has become the most widely diagnosed non-skin 
cancer in men in the United States [275]. The fact that 1410 men need to be screened and 






only about the usefulness of prostate specific antigen screening, but also about the 
clinical management, of PCa. Indeed, most PCa are slowly growing, and only the 
aggressive ones eventually spread to other organs and require early diagnosis and 
effective treatment. The current standard for PCa diagnosis remains biopsy and 
histopathology. While PCa with Gleason score ≤ 6 (e.g. 3+3) is considered to be low-risk 
and is left without active treatment, PCa with Gleason score ≥ 7 (e.g. 3+4) is considered 
to be high-risk and is often treated with radical prostatectomy, androgen deprivation 
therapy, radiation, and/or chemotherapy. Nonetheless, the subjective nature of 
histopathology leads to inevitable discordance among pathologists. Especially for the 
differentiation between Gleason score 6 and 7, the inter-observer discordance can be up 
to 40% [277], which may result in overtreatment for some low-risk tumors and 
undertreatment for some high-risk tumors. Our study provides an opportunity towards 
more accurate prediction of aggressiveness. Because CE accumulation is quantifiable and 
is significantly (~5 fold) greater in Gleason grade 4/5 compared to that in Gleason grade 
3, it presents a promising molecular marker to improve the current PCa diagnosis. 
Notably, massive CE accumulation only occurs in metastases and most of, but not all, 
high-grade PCa (Table 2.1). Moreover, depleting CE significantly impairs PCa 
aggressiveness, including survival, migration, invasion, and growth in vivo. These results 
together suggest that CE accumulation might be used for more accurate prediction of PCa 
aggressiveness. We note that validation of CE as an aggressiveness marker necessitates 
further examination of a large number of tissue biopsies and correlation assessment of CE 






Third, our study heralds the potential of using CE as a therapeutic target for 
treatment of advanced PCa. While often diagnosed in clinically localized stages, PCa 
remains the second leading cause of cancer-related mortality in American men with over 
28,000 projected deaths in 2012 [275].  For men with advanced PCa, androgen 
deprivation therapy is an accepted standard therapy. Despite initial disease control, 
androgen deprivation therapy alone is non-curative and the subsequent development of 
castration-resistant PCa occurs in the lifespan of almost all men who do not succumb to 
non-cancer deaths [185]. There has been a tremendous increase in treatment options 
available for metastatic castration-resistant PCa patients, including novel anti-androgen 
therapy [278] and others. Nevertheless, the effectiveness of current therapies is palliative 
with an improvement in overall survival of 2-5 months compared to placebo. In this study, 
we show that CE depletion by abrogating ACAT activity with avasimibe significantly 
hinders advanced PCa growth via cell cycle arrest and apoptosis induction. One possible 
explanation for such anti-cancer effect of avasimibe, as illustrated in Figure 2.13,  is that 
depleting CE storage disrupts intracellular cholesterol homeostasis and consequently 
reduces the uptake of essential fatty acids, such as AA, which stimulates PCa growth and 
progression [264, 265]. Because CE depletion leads to elevation of free cholesterol levels, 
apoptosis induced by avasimibe could be due to free cholesterol toxicity. The alteration 
of cholesterol metabolism might also be linked to regulation of lipid rafts in PCa [193]. 
Importantly, the CE-depleting drug does not cause detectable toxicity in the non-
transformed cell or in the mouse model. Owing to the much stronger dependence of 
advanced PCa on CE compared to its normal counterparts, cholesterol esterification may 






Blockage of cholesterol esterification with ACAT inhibitors was used to treat 
lymphocytic leukaemia [197], glioblastoma [279], and breast cancer [280] cells in vitro. 
In this work, we demonstrated, for the first time, its effectiveness in suppressing growth 
of aggressive tumor in vivo. We note that avasimibe was previously used to treat 
atherosclerosis [256] but halted by Pfizer due to the lack of effectiveness in reducing 
plaque size. Thus, the present study highlights a novel use of avasimibe to treat advanced 
PCa. Collectively, abrogating ACAT-1 activity offers a potentially effective way of 
treating advanced PCa. 
Finally, given that the PI3K pathway is hyperactivated not only in advanced PCa, 
but also in many other human cancers, including brain, breast, renal, lymphocyte, 
cervical, and lung [67], CE accumulation in LDs might be a common characteristic of 
PI3K-driven cancers. Indeed, CE was found to be a proliferative factor for leukemia 
[197]. And dysregulation of cholesterol metabolism in glioblastoma was shown to be 
driven by PI3K pathway [179]. Future elucidation of the molecular mechanisms by which 
PI3K pathway differentially regulates cholesterol metabolism in cancer cells from 
multiple tissues of origin will determine whether CE is a compelling drug target across 
multiple cancer types. Such studies will further improve current understanding of how 







CHAPTER 3. LABEL-FREE ANALYSIS OF BREAST TISSUE POLARITY BY 
RAMAN IMAGING OF LIPID PHASE 
The work presented in this chapter was published in Biophysical Journal [281]. 
Reprinted with permission from [281]. Copyright © 2012 Biophysical Society. 
The formation of the basoapical polarity axis in epithelia is critical for 
maintaining the homeostasis of differentiated tissues. Factors that influence cancer 
development notoriously affect tissue organization. Apical polarity appears as a specific 
tissue feature that, once disrupted, would facilitate the onset of mammary tumors. Thus, 
developing means to rapidly measure apical polarity alterations would greatly favor 
screening for factors that endanger the breast epithelium. A Raman scattering based 
platform was used for label-free determination of apical polarity in live breast glandular 
structures (acini) produced in 3D cell culture. The CARS signal permitted the 
visualization of the apical and basal surfaces of an acinus. Raman microspectroscopy 
subsequently revealed that in polarized acini lipids were more ordered at the ApM 
compared to BaM, and that an inverse situation occurred in acini that lost apical polarity 
upon treatment with Ca2+-chelator EGTA. This method overcame variation between 
different cultures by tracking the status of apical polarity longitudinally for the same acini. 
Therefore the disruption of apical polarity by dietary breast cancer risk factor, ω6 fatty 






this method, even when the effect was too moderate to permit a conclusive assessment by 
traditional immunostaining method. 
3.1 Introduction 
With advantages over conventional 2D cell culture models that they provide by 
mimicking tissue-specific architectures and functions, 3D cell culture models have been 
increasingly used in a broad range of research, including epithelial morphogenesis, tumor 
biology, cell migration, regenerative medicine, and drug screening [282-284]. In 
particular, increased knowledge in mammary gland morphogenesis and neoplastic 
transformation has been obtained from studies using 3D culture of different types of 
mammary epithelial cells that take into account alterations in tissue architecture (i.e., the 
specific cellular organization within an assembly of cells) to decipher the mechanisms 
that control cell proliferation, survival, differentiation and resistance to chemotherapeutic 
drugs [285-295]. However, a wide implementation of the evolving paradigm of 
physiologically relevant 3D culture has been hampered by the lack of proper visualization 
tools to study tissue phenotypes. A tremendous challenge to quantitatively measure 
cellular responses in 3D cultures by conventional fluorescence microscopy is the 
inefficient diffusion of fluorescent dyes in thick tissue samples [283] and the fluorescent 
background triggered by the ECM used as cell culture substratum [296]. Continuous 
analyses of cellular responses over periods of time are limited to bright field microscopy 
and the occasional GFP-tagged expression of a specific protein. Therefore, innovations in 
label-free analysis of cellular responses are crucial to fully exploit the benefits of 3D 






An important area of investigation is the alteration of tissue architecture that 
precedes tumor development. Inhibiting or reversing such alterations would play a key 
role in the design of prevention interventions that are so much needed. A number of 
factors that favor cancer development have been associated with changes in tissue 
architecture. Indeed, epidemiological and/or animal studies reported that estrogen and 
high fat diet [297], as well as obesity [298] and alcohol consumption [299] could modify 
mammary morphogenesis (notably the density of epithelial structures, a factor known to 
influence breast cancer risk).   
 
Figure 3.1 Organization of Mammary Acinus. TJ: tight junction; D: 
desmosome; GJ: gap junction. 
 
Models that mimic phenotypically normal breast glandular differentiation exist 
and have been used to unravel pathways involved in the initiation of tumors. Cells are 
cultured in the presence of EHS-derived ECM, which resembles a BM, and functionally 






3522 S1, complete tissue polarity axis [290, 295, 296] (Figure 3.1). This axis largely 
determines the functional integrity of epithelia and includes both apical polarity and basal 
polarity [292, 300, 301]. Basal polarity is determined by the presence of specific cell-BM 
contacts [292]. Apical polarity is characterized by the polarized distribution of 
cytoplasmic organelles [301-304]  and the segregation and retention of specific proteins 
and lipids in distinct ApM and BaM domains due to the presence of apical tight junctions 
[305, 306]. Functionally, the BaM facing the extracellular compartment maintains 
differentiation and survival, whereas the ApM facing the luminal (external) compartment 
mediates physiological states (e.g., quiescence) and exchange functions (e.g. absorption 
and secretion) [301]. Tight junctions are formed by transmembrane proteins connected to 
cytoplasmic proteins at the most apical side of cell-cell junctions [307, 308]. The 
redistribution of tight junction proteins away from apical sites is an indicator of the 
disruption of apical polarity [309-311]. Importantly, proteins normally located at the 
apical junctional complex have been implicated in the control of tumor development [295, 
312]. Moreover, loss of apical polarity is necessary for cell cycle entry, and is one of the 
earliest changes observed in tissue architecture in breast neoplasia [293, 295, 313]. 
Interestingly, smoking, the key factor in the development of lung cancer, has been shown 
to alter apical polarity in the lung epithelium [314]. Therefore the status of tissue polarity 
constitutes a critical readout to assess epithelial integrity and homeostasis.    
Currently, immunofluorescence imaging of fixed cell culture for apical polarity 
markers is needed to determine the status of apical polarity. This method prevents 
dynamic screening of factors that could control epithelial homeostasis. Also the 






[293, 313, 315]. Consequently loss of apical polarity in a small, yet significant fraction of 
the acini population might be easily blurred by variation between different cultures. Thus, 
a large number of acini have to be analyzed to achieve statistical significance, which 
implies ineffectiveness of the current immunostaining method.  
In polarized epithelial cells, not only proteins but also lipids are differentially 
distributed on apical and BaM [303, 304]. The ApM is strongly enriched in sphingolipids, 
which, together with cholesterol, form continuous liquid-ordered assemblies with 
restricted mobility. In contrast, the BaM has less raft coverage and thus, is in a less 
ordered phase [303, 304]. Different degrees of lipid ordering have been shown to produce 
distinct Raman spectral profiles in live tissues [316-318], which opens the possibility for 
applying this method to 3D cultures of mammary acini.  
As a non-invasive and label-free analytical method, Raman spectroscopy has been 
widely used in biomedical research [319]. In particular, the analysis of lipid composition 
by Raman spectroscopy is well established in the skin [318], eye lens [317], and nerve 
fibers [320]. Since the first measurement of living cells [321], Raman spectroscopy has 
been extensively applied to quantitative studies of biological systems [322-324]. 
However, the application of Raman scattering to high-speed biological imaging is 
hindered by the very weak spontaneous Raman signals. In order to enhance the signal 
level, CARS microscope has been developed [325].  By focusing the excitation energy on 
the single Raman band and coherent addition of the scattering field, single-frequency 
CARS microscopy has been employed to visualize lipid-rich structures, including cellular 
membranes, myelin sheath, and adipocytes, at the speed of a few microseconds per pixel, 






multiplex CARS (M-CARS) microscopy using a narrowband and a broadband pulse has 
been developed [329, 330] and applied to the study of LDs in 3T3-L1 cells at a speed of 
20 ms per pixel [331, 332]. Another important development is hyperspectral CARS 
enabled by automatic wavelength scanning of a picosecond laser [333].  
To fully appreciate the potential of high-speed vibrational imaging by CARS and 
quantitative spectral analysis by spontaneous Raman, Cheng and coworkers developed a 
compound Raman microscope that couples fast CARS imaging of a live biological 
sample with confocal Raman spectral analysis at points of interest [334]. The compound 
Raman microscope has been applied to quantitative analysis of LDs in live cells, tissues, 
and model organisms [334, 335]. 
In this work, we present a new application of compound Raman microscopy to 
label-free analysis of live cell membrane in 3D culture. Specifically we investigate how 
lipid ordering of ApM and BaM could be used to characterize apical polarity in live 
mammary acini. We took advantage of a  high-throughput cell culture technique that 
permits the formation of acini in the presence of diluted EHS on a glass surface [313], 
enabling direct microscopic evaluation of apical polarity. We note that cell morphology 
and organization in 3D culture are completely different from those in flat monolayer 
culture. The cells in the acini tightly adhere together to form ball-like ApM and BaM, 
with diameter of 5 and 30 µm, respectively. This feature allowed acquisition of confocal 
Raman spectra of ApM and BaM with lateral resolution around 0.4 µm and axial 
resolution around 4 µm. By fast CARS imaging followed by confocal Raman 
spectroscopy of membranes at the equatorial plane of live acini, we show that the relative 






(P) and nonpolarized (Non-P) mammary epithelia with high sensitivity and specificity. 
This method offers new opportunities for the study of environmental factors that 
influence epithelial homeostasis.  
 
3.2 Experimental Section 
3.2.1 3D Culture of Human Mammary Acini 
Non-neoplastic human mammary epithelial HMT-3522 S1 cells were cultured at 
37ºC in 5% CO2, in chemically defined H14 medium. H14 medium consists of 
DMEM/F12 (Gibco/BRL, St Louis, MO) with 250 ng/ml insulin (Boehringer Mannheim, 
Indianapolis, IN), 10 µg/ml transferrin (Sigma, St Louis, MO), 2.6 ng/ml sodium selenite 
(BD Biosciences, Bedford, MA), 10–10 M estradiol (Sigma), 1.4 µM hydrocortisone (BD 
Biosciences),  5 µg/ml luteotropic hormone (Sigma), and 10 ng/ml EGF (EGF; BD 
Biosciences). H14 medium was routinely changed every 2-3 days. The high-throughput 
3D culture was previously described (Ref. 32). Briefly cells were plated at a density of 
41,520 cells / cm2 in half the volume of medium for each 35 mm glass bottom dish. The 
other half of the medium containing 10% EHS material from Matrigel™ (BD Bioscience) 
was dripped on top of cells 5 min after cell seeding. The culture medium was changed 
every two to three days with EGF omitted after day 7. Acinar morphogenesis is routinely 
observed by day 8 to 10. 
Treatment with disruptors of apical polarity was applied upon acini formation. 
Incubation  with 1.5 mM EGTA began from day 10 and lasted for 24 hours, a time frame 
shown to effectively disrupt apical polarity in the majority of mammary acini [293]. 






3D culture. The same H14 medium was used throughout the treatments with different 
modulators of apical polarity. As shown in Figure 3.2, we were able to track the same 
mammary acini, in gridded glass-bottom culture dishes, undergoing treatment by 
transmission and CARS imaging. 
 
Figure 3.2 Longitudinal tracking of acini undergoing treatments to disrupt 
apical polarity. Acini were grown on gridded glass bottom culture dishes for 
10 days using the high throughput method. They were located by CARS and 
transmission microscopy imaging before and after treatment with either 
EGTA or AA. Scale bars, 50 µm. 
 
3.2.2 Immunostaining 
Immunofluorescence staining of cells in 3D culture was performed as previously 
described [315]. Cells were permeabilized with 0.5% Triton X-100 (Sigma) for 15 min in 
cytoskeleton buffer [100 mM NaCl, 300 mM Sucrose, 10 mM Pipes pH 6.8, 5 mM 
MgCl2, 1 mM pefabloc, 10 µg/ml aprotinin, 250µM NaF], then fixed in 10% formalin 
(Sigma) for 20 minutes at room temperature. Antibodies against ZO-1 (Invitrogen catalog 






concentration), and hScrib (Santa Cruz catalog # SC-55543, 5 µg/ml final concentration) 
were used. Alexa Fluor 488 phalloidin (Molecular Probes, 5 units/ml final concentration) 
was used to image polymerized actin. Nuclei were stained with 4’, 6-diamino-2-
phenylindole (DAPI; 0.5µg/ml) and samples were mounted in ProLong antifade solution 
(Molecular Probes) and stored at -20ºC until use. 
 
3.2.3 Compound Raman Microscopy and Spectrum Analysis 
A compound Raman microscope, which integrates CARS and confocal Raman 
microspectroscopy on the same platform, was used for label-free analysis of apical 
polarity. In our apparatus, two synchronized 5-ps, 80 MHz laser oscilators (Tsunami, 
Spectra-Physics Lasers) are temporally synchronized and collinearly combined into a 
laser-scanning inverted microscope (FV300+IX71, Olympus).  Pump and Stokes lasers 
were tuned to 707 nm (14140 cm-1) and 885 nm (11300 cm-1), respectively, to be in 
resonance with the CH2 symmetric stretch vibration at 2840 cm
-1. Combined beams were 
focused into the specimen through a 60x water immersion objective with a 1.2 numerical 
aperture (UPlanApo/IR, Olympus). The forward CARS signal was collected by an air 
condenser with a 0.55 numerical aperture, transmitted through a 600/65 nm bandpass 
filter, and detected by a PMT (H7422-40, Hamamatsu). Average acquisition time for a 
512 x 512 pixels CARS image was 1.12 second, and the combined Stokes and pump laser 
power at the specimen was kept constant at 40 mW. Following CARS imaging, the 
Stokes beam was blocked and the pump laser induced Raman scattering signal was 
directed toward the spectrometer (Shamrock SR-303i-A, Andor Technology), which was 






3100 cm-1. The spectrometer pinhole was 50-μm in diameter, which provides an axial 
resolution of about 4 μm. The lateral resolution was about 0.4 µm. Each Raman spectrum 
was acquired in 10 seconds, and pump laser power at the specimen was maintained at 15 
mW. No tissue damage was observed. 
To determine the location of the ApM and BaM, we first adjusted the focus to the 
equatorial plane of an acinus based on the CARS image (see Figure 3.3A). We then 
zoomed into the apical site of the acinus by CARS (see Figure 3.3B) and positioned the 
laser focus for Raman measurement on the most apical pole of certain epithelial cells in 
the acinus (e.g. the location indicated by the magenta circle in Figure 3.3B). We then 
moved the focus to the basal site of the acinus (see Figure 3.3C) and positioned the focus 
for Raman measurement on any location on the BaM of certain epithelial cells of the 
acinus (e.g. the location indicated by the blue circle in Figure 3.3C). 
For Raman analysis, two spectra were taken, one from the cell (membrane, 
cytoplasm, or nucleus) and the other from the glass. The glass contribution was removed 
by first scaling the glass profile to make its intensity of the peak-free region (2000-2600 
cm-1) the same as that of the cell profile, and then subtracting this modified glass profile 
from the cell profile. The fluorescence background in the resultant Raman spectrum was 
fitted by a 4th order polynomial function and further removed. The 4th order polynomial 
fit was achieved by choosing six points in the spectrum lacking any spectral features. For 
a better comparison of spectral patterns, each Raman spectrum was then normalized by 
dividing by the peak intensity of the band around 2935 cm-1 over the spectral range 2770 
- 3070 cm-1. Then, the normalized Raman spectra were least-squares fitted as a sum of 







Figure 3.3 Label-free analysis of lipids in polarized mammary acini. (A) 
CARS image of a mammary acinus with apical and basal poles. (B) CARS 
image of the orange square in A shown at higher magnification. Crosses 
within purple and black circles, which indicate ApM and cytoplasmic regions 
of the cell respectively, are the positions for confocal Raman spectral 
measurement. (C) CARS image of the blue square in A shown at higher 
magnification. Crosses within blue and green circles, which indicate BaM and 
nucleus regions of the cell respectively, are the positions for confocal Raman 
spectral measurement. (D) Normalized Raman spectra of regions within ApM 
(purple line), BaM (blue line), cytoplasm (Cyto, black line), and nucleus (Nuc, 
green line). (E-H) Lorentzian curve fitting for Raman spectra of ApM, BaM, 
Cyto, and Nuc. Original spectra are shown in the same color as in D. The 
Lorentzian fitting curves are shown in green. The areas under Raman bands 
around 2850 cm-1 and 2885 cm-1 are highlighted with green stripes. The 
cumulative fitted curves are shown in orange. (I) Ratio A2885/A2850 (R) for 
ApM and BaM (R for Cyto equals 1.56, and R for Nuc equals 4.11). (J) 
Fluorescence image of the mammary acinus in A labeled for apical polarity 
marker ZO-1(red) and DNA (DAPI, blue; nine nuclei are seen in this focal 
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where w is the wavenumber, Aj is the area under the j
th band, j is the width and j is the 
center wavenumber of the jth band. Peak wavenumbers and widths for curve fitting are 
listed in Table 3.1. The corresponding assignments of Raman peaks are listed in Table 
3.2 [320, 336].  
 
Table 3.1 Curve fitting parameters. The parameters of the seven Lorentzian bands 
used to fit the 2770 – 3070 cm-1 regions of all Raman spectra. 
Peak center (Ω
j
, cm-1)  Peak width (Γ
j
, cm-1)  
2845-2855  13.5  
2856.5-2870 23.0  
2875-2888  22.0  
2885-2910  32.0  
2930-2945  47.0  
2958-2972  30.0  
2980-3000  32.0  
 
For Raman analysis of membrane lipid ordering, CARS microscopy was first used 
to visualize cell membranes of live mammary acini. Details about how to determine the 
location of the ApM and BaM can be found in the Supplemental Materials and Methods. 
The intense bands around 2850 cm-1 and 2885 cm-1 have been assigned to symmetric and 
asymmetric CH2 stretching, respectively. The band around 2885 cm
-1 is markedly 
enhanced by Fermi resonance in ordered lipid packing, whereas the band around 2850 
cm-1 is not affected by structural changes of the lipid hydrocarbon chains [317, 318, 336]. 
Thus, the degree of lipid ordering can be represented by the ratio between the areas under 
Raman bands at 2885 cm-1 (A2885) and 2850 cm
-1 (A2850), A2885/A2850 (R) [317, 318, 336].  
ApM_R (or BaM_R) was the degree of lipid ordering of ApM (or of BaM).  A 
ratio ApM_R/BaM_R was defined to represent the relative degree of lipid ordering of 






Table 3.2 Assignments of Raman peaks. 
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differentiate between P and Non-P mammary acini, a ROC curve was generated by 
plotting sensitivity vs. (1-specificity) and the AUC was calculated. Based on the ROC 
curve, the best cutoff of ApM_R/BaM_R was determined. 
 
3.2.4 Statistical Analysis 
Student’s t test was used to (1) compare the degree of lipid ordering (R) of ApM 
and that of BaM for P and Non-P mammary acini, respectively, (2) compare the ratio 
ApM_R/BaM_R of P mammary acini and that of Non-P mammary acini, and (3) 






p < 0.05 was considered statistically significant. The exact p values are shown in the 
corresponding figure captions. 
 
3.3 Results and Discussion 
As CARS permits selective imaging of lipid-rich structures, it was used to 
visualize the ApM and BaM in the equatorial plane of live mammary acini. Substantial 
CARS signals arose from the lipid-rich ApM and BaM of the mammary acinus, whereas 
weak CARS signals came from the lipid-poor cell nucleus (Figure 3.3A-C). This strong 
contrast easily distinguished, in a label-free manner, the different compartments of 
individual cells that form the single-layered epithelium. Considerable CARS signals also 
arose from the cytoplasmic space, possibly due to lipid-rich organelles such as 
endothelium reticulum, LDs and mitochondria. An important characteristic of the 
morphogenesis of acinar structures is the narrower width of the apical pole compared to 
the basal pole [313]. This characteristic was clearly outlined by CARS (Figure 3.3C). 
Confocal Raman microspectroscopy was further used to analyze lipid phases of ApM and 
BaM.  
As shown in Figure 3.4, both ApM and BaM are present within the axial 
resolution of confocal Raman microspectroscopy (~4µm). Although the fingerprint 
regions on Raman spectra of ApM and BaM (Figure 3.5) did not show clear difference 
due to the low signal to noise ratio, the C-H stretching regions were very distinct (Figure 
3.3D), indicating unique compositions of these cellular compartments. Moreover, based 







Figure 3.4 Depth-resolved CARS images of the apical and basal poles of a 
mammary acinus. Arrowheads indicate the ApM in A and BaM in B. Scale 
bars, 10 µm. 
 
between the areas under Raman bands at 2885 cm-1 (A2885) and at 2850 cm
-1 
(A2850), A2885/A2850 (R), were different among ApM, BaM, cytoplasm and nucleus (Figure 
3.3E-H). In particular, R was much higher in ApM relative to BaM in the majority of P 
acini (n = 40) (Figure 3.3I). The polarized status was confirmed by the apical location of 
ZO-1 (Figure 3.3J). These results indicate that in the 3D acini, we are able to obtain 
distinctive Raman spectra from ApM and BaM, which are visualized by CARS. 
Moreover, the degree of lipid ordering, quantified by the ratio A2885/A2850 (R), is different 
between ApM and BaM.  
In order to induce a significant loss of apical polarity in the acini population, 10-
day 3D cultures were incubated with 1.5 mM EGTA as shown previously [293]. Note 
that EGTA does not affect membrane lipid ordering (R) in mammary epithelial cells (S1 
cells in 3D culture on day 1) before apical polarity has been formed (Figure 3.6). Raman 
spectra were then recorded for the nonpolarized (Non-P) mammary acini (i.e., with 






90% of acini are not apically polarized after EGTA treatment) and from control cultures 
(usually ~25% of acini are not apically polarized in routine 3D culture) (Figure 3.7). 
Breast epithelial cells treated with EGTA became round due to the loosening of cell-cell 
 
Figure 3.5 Raman spectra (900 – 1800 cm-1) of ApM, BaM, cytoplasm, and 




Figure 3.6 CARS images and membrane lipid ordering (R) of S1 cells in 3D 
culture before apical polarity has formed. EGTA was added on day 1 of 3D 
culture. Analysis was performed before and after 24h EGTA treatment. 
Control dishes were analyzed at the same time points. n = 5 cells. No 
statistical difference was found among the four compared groups (one-way 
ANOVA). Crosses indicate the locations for Raman spectral analysis. Scale 






contacts, which leads to acini with bumpy outer contour (Figure 3.7B). This morphology 
was in contrast with the control population in which acini usually had a smooth 
circumference regardless of their polarity status (compare Figure 3.3A to Figure 3.7A). 
Yet, lipid ordering (R) was consistently lower in ApM compared to BaM in Non-P 
mammary acini regardless of the change in cell shape, indicating that disruption of apical 
polarity per see is sufficient to show the reorganization of lipids (Figure 3.7).  
To confirm that lipid ordering (R) was statistically different between ApM and 
BaM in both P and Non-P mammary acini, it was analyzed in 40 P and 40 Non-P 
mammary acini. Indeed lipid ordering was significantly higher in ApM compared to BaM 
for P mammary acini; whereas it was significantly lower in ApM compared to BaM for 
Non-P mammary acini (Figure 3.8A). The result for P mammary acini is consistent with 
chromatography analysis of the lipid composition of polarized intestinal cells that shows 
more ordered lipids within ApM than within BaM [303, 304, 337]. In addition, lipid 
ordering (R) was significantly higher for the ApM of P mammary acini compared to that 
of Non-P mammary acini, and significantly lower for the BaM of P mammary acini 
compared to that of Non-P mammary acini. The alterations in membrane lipid ordering in 
Non-P mammary acini compared to P mammary acini might be due to the disruption of 
tight junction, which leads to improper sorting of membrane lipids including cholesterol 
and sphingolipids. Although the specific lipid compositions of ApM and BaM remain to 
be investigated, the lipid ordering shows potential to distinguish P and Non-P mammary 
acini (Figure 3.8A). In order to differentiate P and Non-P mammary acini with both high 








Figure 3.7 Label-free analysis of lipids in nonpolarized mammary acini. 
Shown are the CARS image, the Raman spectra of ApM and BaM with 
Lorentzian fitting, the ratio A2885/A2850 (R) for ApM and BaM, and 
immunofluorescence labeling for ZO-1(red; arrows indicate the presence of 
ZO-1 at the basal side of the acinus) for a nonpolarized (Non-P) mammary 
acinus in the control group (A) and a Non-P mammary acinus in the EGTA-
treated group (B). Nuclei are counterstained with DAPI (blue). Scale bars,10 
µm. 
 
ratio represents the relative degree of lipid ordering of ApM (ApM_R) compared with 
that of BaM (BaM_R). Raman scans from different ApM and BaM locations inside an 
acinus (P or Non-P acinus) did not produce statistically different lipid ordering ratios 
(Figure 3.9). Importantly, the lipid ordering ratio was significantly higher for P mammary 
acini compared to Non-P mammary acini with much smaller p value than that obtained 
from the comparison of these same populations based solely on ApM_R or on BaM_R 
(Figure 3.8B). This result suggests that P and Non-P mammary acini can be distinguished 
with higher statistical significance when using the lipid ordering ratio compared to the 







Figure 3.8 Distinction between ApM and BaM in polarized and nonpolarized 
acini. (A) Comparison of the ratio A2885/A2850 (R) in ApM and BaM 
regions for both polarized (P) mammary acini and nonpolarized (Non-P) 
mammary acini. (B) Comparison of the relative lipid ordering ratio 
ApM_R/BaM_R in P mammary acini and Non-P mammary acini. (Student's 
t-test, * p < 5.0E-5, ** p < 1.0E-5, *** p = 4.0E-20, n=40 acini). 
 
The ratio of the symmetric C-H stretching mode intensities (peak height), I2885/I2850 (R’), 
is a well accepted representation of the packing order of acyl chains [317, 318, 320, 338]. 
However, multiple peaks overlap within the C-H stretching region, which may cause 
inaccuracy when using peak height to calculate lipid ordering. Therefore in the results 
presented above we have used Lorentian fitting to obtain peak areas for each Raman 
bands and we have represented lipid ordering by the ratio of the areas R. The fitting 
results including parameters, statistics, and residuals can be found in Table 3.3 and Figure 
3.10. In order to compare our results with previous work that used R’ [318, 338], we also 
calculated R’ for the same 40 P and 40 Non-P acini used for R calculation in Figure 3.8. 
R’ fell mainly between 1.5 and 2 (for liquid R’ equals 0.7, and for crystal it equals 2.2 
[318, 338]) and showed the same trends as with R (compare Figure 3.8 to Figure 3.11). 






from R calculations, suggesting that R would perform better in distinguishing P and Non-
P acini. 
 
Figure 3.9 Reproducibility of ApM_R/BaM_R measurement. For both P and 
Non- P acini, ApM_R/BaM_R ratios were obtained based on three Raman 
scans performed at 3 different locations (labeled as ApM1, ApM2, ApM3) of 
ApM. No statistical significance was found using ANOVA test. 
 
Table 3.3 An example of fitted curve parameters (peak center, peak width, and area under 
peak) and statistics (reduced Chi-square and adj. R-square). The statistics reflect the 


















2866.9 (3.0)  23.0  6.5 (1.2)  
2884.4 (1.7)  22.0  10.0 (1.7)  
2900.1 (2.1)  32.0  16.3 (1.9)  
2935.4 (0.9)  47.0  62.0 (1.8)  
2960.0 (2.2)  30.0  9.7 (1.6)  
2986.5 (1.3)  32.0  11.6 (0.9)  
 
To determine the ability of the lipid ordering ratio, ApM_R/BaM_R, to 
distinguish P from Non-P mammary acini, the histogram of the number of acini was 
plotted as a function of this ratio (Figure 3.12). The plots for P and Non-P mammary 






distribution curves. An overlap between plots indicated that proper cutoff was required in 
order to distinguish P from Non-P mammary acini with both high sensitivity and  
 
 




Figure 3.11 Distinction between ApM and BaM in polarized (P) and 
nonpolarized (Non-P) acini, using the ratios I2885/I2850 (R’) and 
ApM_R’/BaM_R’. (A) Comparison of the ratio I2885/I2850 (R’) in ApM and 
BaM for both P mammary acini and Non-P mammary acini. (B) Comparison 
of the ratio ApM_R’/BaM_R’ in P mammary acini and Non-P mammary 
acini. (Student's t-test, * p < 0.05, ** p < 5.0E-4, *** p = 6.1E-6, n=40 acini). 
 
specificity. A ROC curve was built to illustrate the tradeoff between sensitivity and 






possible cutoffs of the lipid ordering ratio. The closer the curve comes to the 45-degree 
diagonal (shown as a thin black line in Figure 3.12B) the less accurate the diagnostic test. 
The big AUC (=0.98) clearly demonstrated the ability of the lipid ordering ratio to 
accurately differentiate P from Non-P mammary acini (Figure 3.12B). More importantly, 
the ROC curve provided a way to obtain the desired degree of sensitivity at the cost of 
specificity. Here, both high sensitivity (=0.925) and specificity (=0.925) were gained with 
a cutoff of 1.0 (lipid ordering ratio = 1.0). Therefore, it is possible to quantitatively and 
accurately distinguish P from Non-P mammary acini by the lipid ordering ratio with both 
high sensitivity and high specificity.  
 
Figure 3.12 Sensitivity and specificity of the relative lipid ordering ratio in 
identifying polarized and nonpolarized acini. (A) Histogram plot of the 
number of acini as a function of the lipid ordering ratio (Blue: nonpolarized 
(Non-P) mammary acini, Red: polarized (P) mammary acini). (B) ROC curve 
illustrating the ability of lipid ordering ratio to distinguish P and Non-P 
mammary acini (green line). The ROC curve of two indistinguishable 
populations, represented by the black line, is included for comparison. 
 
As an application of the label-free approach developed above to measure polarity 
status, disruption of apical polarity was tracked over time in mammary acini undergoing 






[42, 339-343]. Particularly, high dietary intake of ω6 PUFAs has been associated with 
increased breast cancer risk [344]. Moreover, certain dietary interventions with fatty 
acids were shown to lead to rapid and potentially beneficial changes in ω3/ω6 PUFA 
ratio in the serum and breast adipose tissue [345, 346]. So far it is unknown whether ω6 
PUFA could participate in the initiation stage of breast neoplasia by disrupting apical 
polarity. The impact of AA on apical polarity was assessed in series of eight live acini 
before and after treatment with 60 M AA. CARS images of the same mammary acini 
were taken before and after a 4-day AA treatment and the status of apical polarity was 
evaluated based on lipid ordering ratio (Figure 3.13A, 3.14). After excluding the acini 
that were nonpolarized already before AA treatment, a statistically significant loss of 
apical polarity (~30% of the population studied) was measured in AA-treated acini 
(Figure 3.13B). In contrast, examination of the apical location of tight junction protein 
ZO-1 by immunostaining in the same sets of samples and in 100 acini randomly chosen 
in each experiment, failed to reveal a statistically significant loss of apical polarity in 
AA-treated acini population (Figure 3.13C, 3.15).  
The results shown in Figure 3.13 demonstrate that although immunostaining of 
tight junction proteins has been commonly used to determine the status of apical polarity 
[293, 313, 315], it is not very effective to detect significant loss of apical polarity induced 
by dietary factors  in a small portion of the acini population. This ineffectiveness of 
immunostaining method is largely due to the variation between different cultures, given 








Figure 3.13 Measurements of the polarity status in acini before and after 
treatment with ω6 fatty acid.  Acini were incubated with either ethanol vehicle 
or 60 µM AA from day 8 to 12 of 3D culture. (A) Status of apical polarity 
(polarized, P or nonpolarized, Non-P) based on the lipid ordering ratio 
(ApM_R/BaM_R, number indicated in parenthesis; R = A2885/A2850) for the 
same group of acini before and after AA treatment as measured by the Raman 
scattering-based method. (B) Percentage of acini that have lost apical polarity 
in the control and AA-treated groups at day 12 (after treatment with vehicle or 
with AA) compared to day 8 (before treatment) detected by the Raman 
scattering-based method (*p value=0.0066, n=3 sets of 8 acini). (C) 
Percentage of acini with ZO-1 apically localized in vehicle control and AA-
treated groups at day 12 of 3D culture (using the sample sets analyzed in B). 
Scale bar, 5 µm. 
 
By tracking the status of apical polarity for the same live acini before and after treatment 
with the Raman method, we are able to take into account only the acini that are apically 
polarized before treatment and then readily measure how many of them lose apical 






apical polarity by discarding false positives, that is, the acini that would not have been 
apically polarized from the start. 
 
 
Figure 3.14 Immunofluorescence images of AA-treated mammary acini. 
Immunostaining for ZO-1 (red) and labeling for DNA (DAPI, blue) in acini 
following treatment with AA shown in Fig. 5A. Scale bar, 5 µm. 
 
 
Figure 3.15 Blind scoring of ZO-1 localization in control and AA-treated acini 
populations. Acini in control and 60 µM AA-treated groups were fixed and 
immunolabeled for ZO-1 in three independent experiments (the same ones 
shown in Fig. 5). Here, at least 100 acini were randomly chosen and scored 
(ZO-1 staining apically localized or not apically localized) per experiment and 
results were analyzed by Student’s t-test. 
 
To understand the origin of reduced lipid ordering in Non-P acini, we further 
studied how AA treatment might affect the tight junction complex. It is possible that the 
effect of AA might only encompass ZO-1, leaving the rest of the tight junction intact. To 
rule out this possibility, the effect of AA was studied not only on ZO-1 but also on ZO-2, 








Figure 3.16 Distribution of apical polarity-related proteins in polarized (P) and 
nonpolarized (Non-P) acini. Dual staining for tight junction core proteins ZO-
1 and ZO-2 (A), ZO-1 and cytoskeleton component actin (B), and 
immunolabeling for apical polarity organizer hScrib (C) in P mammary acini 
in the  control group (vehicle, Veh) and Non-P mammary acini in ω6 AA-
treated group. Cell nuclei were labeled with DAPI (blue color). (D) 
Histograms of the percentages of acini with apically located ZO-1 (p = 
0.0167), ZO-2 (p = 0.0026), hScrib (p = 0.0347) and actin (p = 0.0043), (n=3, 
V: Veh, A: AA). * p < 0.05; ** p < 0.01. Scale bar, 5 µm. 
 
components of the junctional complex and the cytoskeleton [347-349]. Immunostaining 
performed in a new set of experiments revealed that the two tight junction core proteins 
ZO-1 and ZO-2 colocalized in more than 90% of the cases when apically located and 
were significantly mislocalized upon AA treatment (Figure 3.16A) but did not overlap 
when away from the apical pole, suggesting that AA affects the tight junction complex 
globally. ZO-1 is the main protein that stabilizes the tight junction to the actin 
cytoskeleton in cells [347, 349, 350], therefore a severe disruption of the tight junction 






had apically polarized ZO-1, staining for polymerized actin was strongest at the apical 
side of the cells (Figure 3.16B). This is expected since the actin cytoskeleton serves as a 
framework to which tight junction complexes can bind and be secured in place [349]. 
However, in the cells that had mislocalized ZO-1, the actin cytoskeleton was diffuse 
(Figure 3.16B), in agreement with a disruption of the tight junction complex. Tumor 
suppressor  hScrib [312] plays a critical role during the initial formation of the tight 
junction complex [351] and disruption of tight junctions might perturb its function. In 
control acini, hScrib was located at the apical side with some lateral positioning, as 
shown by immunostaining. However, in acini treated with ω6 AA, hScrib became 
mislocalized as revealed by a diffuse staining pattern (Figure 3.16C). Although the 
immunostaining method cannot always detect a significant difference between control 
and treated groups (Figure 3.13C, 3.14), there have been some instances in which the AA 
treatment induces statistically significant loss of apically located ZO-1, ZO-2, hScrib, and 
actin, as shown in Figure 3.16D. These observations suggest that AA profoundly affects 
apical polarity, including the integrity of hScrib tumor suppressor localization. 
Specifically, they indicate that AA causes acinar cells to lose apical organization via a 
disruption of the tight junction complex, because two of the tight junction core proteins 
redistribute away from the apical pole and tight junction anchorage to the actin filament 
network is destabilized. Considering the key role of actin filaments in maintaining the 
integrity of cell membranes, cytoskeleton disruption is consistent with the reduced lipid 
ordering in the ApM as detected by the Raman analysis. Therefore the lipid ordering ratio 
is a powerful way to measure modifications in tissue polarity, and thus, tissue 






Our technique can be potentially used, in association with the breast cell model, 
as a screening method of risk factors for breast cancer as well as a screening method for 
chemopreventive agents in a similar way as what scientists are starting to do with cancer 
cells. In the latter case, cancer cells placed in 3D culture form tumor nodules that are then 
treated with potential anticancer drugs to test the cytotoxicity of these agents. In our 
study we are working with non-neoplastic cells based on increasing evidence from cell 
culture and patient studies that loss of apical polarity is a very early sign of a 
preneoplastic change [293]. There are currently no ways to test for dietary or chemical 
compounds that could act as agents to initiate and prevent the development of breast 
tumors. We are proposing that our apical polarity measurement method in 3D cell culture 
of non-neoplastic cells would permit accurate screening of deleterious factors for breast 
health (that would induce loss of apical polarity) and also preventive factors (based on the 
reestablishment of apical polarity by these factors or their effect to prevent apical polarity 
loss normally induced by other factors). The possibility of live cell detection with Raman 
technology will permit the study of sequential effects of factors of interest, e.g., to assess 
whether factor B restores apical polarity previously altered by factor A. 
We have demonstrated that a Raman scattering based platform can be used to 
provide label-free determination of apical polarity of live mammary acini in 3D culture. 
In this method the lipid configurations within apical and BaM are measured by high-
speed CARS imaging integrated with confocal Raman analysis. Notably, the derived ratio 
of the degree of lipid ordering appears superior to immunofluorescence-based analysis of 
fixed samples to determine the presence or disruption of apical polarity. This method has 






lose apical polarity due to the effect of AA, a risk factor for breast cancer development. 
The proposed method provides an unprecedented label-free screening platform for rapid 
identification of risk factors that initiate the very early stage of epithelial neoplasia. 
Moreover, the use of the membrane lipid phase as readout to assess polarity should be 
applicable to other types of epithelia where over 90% of cancers originate. Indeed 
polarity is a common feature of the homeostasis of such tissues and all studies of early 








CHAPTER 4. LABEL-FREE IDENTIFICATION OF MAMMARY ADENOMA AND 
ADENOCARCINOMA BY COHERENT ANTI-STOKES RAMAN SCATTERING 
AND SUM FREQUENCY GENERATION IMAGING 
A portion of the work presented in this chapter was published in Laser & Photonics 
Reviews [217]. Reprinted with permission from [217]. Copyright © 1999-2013 John 
Wiley & Sons, Inc. 
Intact and unstained mammary tissues were examined by a multimodal NLO 
imaging system that allows CARS imaging of lipid-rich structures and SFG imaging of 
type I collagen fibrils. The CARS signals arising from cell membranes and cytoplasmic 
LDs allowed the identification of tumor cells, adipocytes, and endothelial cells. 
Simultaneous CARS and SFG imaging enabled direct 3D visualization of cell 
arrangement and ECM organization, but without the requirement for labeling. Epithelial 
cells that form a single row on the innermost part of the duct were visualized in normal 
mammary glands. In mammary adenomas, abundant wavy collagen fibrils formed a 
smooth outer contour to concentrically wrap the small cluster of tumor cells. In mammary 
adenocarcinomas, epithelial cells showed a ragged contour without an organized 
concentric wrap of collagen around them. These results were verified by histological 
analysis. Quantitative analysis of collagen density indicated that mammary 






adenomas. Taken together, these findings suggest that multimodal CARS/SFG imaging 
could potentially be an intraoperative image-guided tool for assessing tumor margins 
during breast cancer surgery 
4.1 Introduction 
Breast cancer is the most common form of cancer in women, except for non-
melanoma skin cancer, and it is also the leading overall cause of cancer death in women 
between the ages of 20 and 59 [1, 352]. Fortunately, approximately 90% of initial breast 
cancer cases are diagnosed as a localized or locoregional disease, which can be attributed 
to the increased use of screening mammography [353]. Considering the negative impact 
of mastectomy on cosmesis and associated psychological issues of breast cancer patients 
[354], and the equivalent effectiveness of mastectomy and lumpectomy [355, 356], the 
National Institutes of Health has suggested lumpectomy as a primary treatment option in 
the majority of women with early-stage breast cancers [357]. Theoretically, non-
hematological cancers can be cured if entirely removed by surgery, but this is not always 
possible because a single cancer cell, invisible to the naked eye, can re-grow into a new 
tumor. In order to define negative margins that are free of any cancer cells adjacent to the 
boundary of the tissue resection, pathologists need to examine the surgical specimen to 
determine if a margin of healthy tissue is present. As a result, about half of the patients 
undergoing lumpectomy have to suffer repeated surgical procedures called re-excisions 
[358]. Studies have shown that the risk of local recurrence and distant metastasis after 
lumpectomy is positively associated with the appearance of positive margins after the 
first surgery and the numbers of re-excision lumpectomies [359, 360]. Thus, accurately 






lumpectomy. To assist in a complete resection of adenocarcinomas with negative margins 
in a single surgical procedure, we need an efficient intraoperative image-guided tool that 
can distinguish normal breast tissues from malignant tumor tissues [361-364].  
Although histopathology has been the gold standard for cancer diagnosis, it 
cannot be used as an intraoperative image-guided diagnostic tool because histology 
requires time-consuming sample preparation, and it cannot provide 3D and real-time 
information about tissue architecture and organization in the natural state. Recently, 
medical imaging techniques, such as ultrasound [365], MRI [366] and radiofrequency 
spectroscopy [367], have been used as image-guide intervention methods in cancer 
surgery. However, all these imaging techniques only allow visualization of tissue 
anatomy with the resolution of ~1mm, which is not sufficient for accurate determination 
of tumor margins during the surgical phase. In addition to those clinical and diagnostic 
imaging techniques currently in use, optical imaging and spectroscopy are gradually 
becoming popular in the development of novel tumor diagnostic techniques. For example, 
OCT allows cross-sectional imaging of breast cancer in surgery with an endoscope [368, 
369]. Raman spectroscopy has been employed to diagnose epithelial pre-malignant 
lesions and cancers based on chemical composition [370]. Confocal reflectance 
microscopy [371] and elastic scattering spectroscopy [372] have also been used for 
cancer diagnosis in clinical studies. However, their limited resolution or limited 
specificity hampers identification of the organization and composition of normal or 
disease states of mammary glands, which would be vital to the definition of negative 






technique that enables visualization of cellular and subcellular structures with high 
resolution.   
During the past two decades, NLO imaging has opened a new window for cancer 
imaging [373]. In addition to submicron spatial resolution, NLO imaging allows 3D 
imaging of tissue architecture with large penetration depths, which cannot be attained 
using conventional histological techniques or confocal fluorescence microscopy. 
Collective studies have shown that differences in morphology and metabolic activity 
between malignant and non-malignant epithelial cells can be delineated by TPEF imaging 
of endogenous fluorophores, such as NAD(P)H and FAD [374, 375]. A distinct 
advantage of this method is that it avoids the need for any exogenous labeling agents, 
thus eliminating toxicity and safety concerns related to their use. However, based solely 
on the fluorescence signal from endogenous fluorophores, clear images of tumor cell 
structures are difficult to produce. In addition, TPEF is often combined with SHG 
imaging that visualizes type I collagen fibrils within tumor tissues, a major component of 
ECM [376]. 
To visualize biological molecules that cannot bear fluorescent labeling, CARS 
microscopy has been developed for high-speed vibrational imaging of lipid-rich 
structures, such as cellular membranes, myelin sheath, and cytoplasmic LDs [217]. More 
recently, multimodality imaging on a CARS microscope has been realized by 
implementation of SFG and TPEF using the same picoseconds laser sources [217]. The 
application of CARS microscopy to cancer imaging is emerging. Le et al. have 
demonstrated that CARS microscopy is able to visualize lipid-rich tumor cells in vitro 






vibrational imaging of brain tumor [378]. Nevertheless, the ability of CARS microscopy 
to differentiate adenomas from adenocarcinomas has not been demonstrated. Additionally, 
the advantages of integrating CARS and SFG for cancer detection have not been explored.  
In this paper, we investigated whether multimodal CARS/SFG imaging could be 
used to characterize the features of unstained normal mammary gland, adenomas and 
adenocarcinomas in a methylnitrosourea (MNU)-treated female Sprague-Dawley rat 
model.  Tumors induced in rats by administration of chemical carcinogens, such as MNU, 
have the potential to be examined during the multi-step process of carcinogenesis, 
including initiation, promotion, and progression [379, 380]. Here, we observed 
substantial CARS signals arising from the lipid-rich cell membranes and cytoplasmic 
LDs, but weak CARS signals from the lipid-poor cell nuclei. Thus, CARS imaging 
enabled us to identify various cell types, such as tumor cells, adipocytes, and endothelial 
cells, based on cell morphology and cytoplasm/nucleus ratio. Moreover, simultaneous 
CARS and SFG imaging enabled direct 3D visualization of cell arrangement and ECM 
organization without labeling. These results were verified by corresponding staining and 
standard histological analysis. Based on the morphology and 3D arrangement of 
epithelial cells and organization of collagen fibrils, we demonstrated that CARS/SFG 
imaging was able to accurately identify the normal mammary gland and distinguish 
between adenomas and adenocarcinomas. These findings suggest that CARS/SFG 
imaging could become an intraoperative image-guided tool for assessing tumor margins 








4.2 Experimental Section 
4.2.1 Animal Model and Tissue Specimens 
Outbred female Sprague-Dawley rats were placed on a rat chow diet (Harlan Tech, 
Indianapolis, IN) containing 3.30 kcal/g of metabolizable energy. Rats received the 
carcinogen MNU or a control 0.9% saline injection. Tissue specimens for CARS/SFG 
imaging were flash frozen in liquid nitrogen and stored at -80 C. Prior to imaging, tissue 
samples were briefly thawed at room temperature and fixed in 10% neutral-buffered 
formalin. All animal experiments were done with the approval of the Purdue Animal Care 
and Use Committee. 
 
4.2.2 Histological Analysis 
Mammary glands and tumor tissues were fixed in a solution of 10% neutral-
buffered formalin. After fixation, tissues were processed and embedded in paraffin blocks. 
Tissue sections of 5 µm thickness were prepared and stained with hematoxylin-eosin. 
Mammary tumors from MNU-injected animals were classified as adenomas and 
adenocarcinomas based on gross morphology by a board certified pathologist.  Normal 
mammary tissue from saline-injected animals was verified as free of any lesions. 
Histology images were acquired using a Nikon Eclipse E400 microscope (Nikon Corp., 
Tokyo, Japan) equipped with air objectives and a Spot Insight camera (Diagnostic 







4.2.3 CARS/SFG Imaging System 
 
Figure 4.1 Multimodal NLO imaging methods and setup. (A) Energy diagram 
of NLO processes including CARS, SFG, and TPEF. (B) Schematic of a NLO 
microscope which combines CARS, SFG, and TPEF on the same platform. 
Inset window shows the simplified light path. DM: dichroic mirror, M: mirror. 
(C) Emission spectra of SFG signals from collagen fibrils (blue); TPEF 
signals from Hoechst 33342-labeled nuclei (green); and CARS signals from 
LDs (red). 
 
A multimodal NLO microscope which allows CARS, SFG, and TPEF imaging on 
a single platform (Figure 4.1B) has been previously described [217]. The energy 
diagrams of CARS, SFG, and TPEF are shown in Figure 4.1A. The details has been 
described in previous chapters. 
Microspectroscopy analysis of mammary tissue components was carried out by 







with an electron multiplying CCD (EM-CCD, Newton-970N-BV, Andor), installed at the 
back port of the microscope, and externally triggered by the confocal scanner. In this 
experiment, we first acquired an image, and then focused the light into a pixel of interest 
by the point-scan mode. The point-scan action triggered the spectrometer to record a 
spectrum of the NLO signals arising from the focal region (Figure 4.1C). 
 
4.2.4 Imaging Conditions 
No sample preparation was necessary before imaging the excised mammary 
tissues. A glass-bottom chamber containing tissues submerged in 1x PBS was placed on 
the microscope for imaging at room temperature. For CARS, SFG, and TPEF imaging of 
fixed tissues, the average powers of the pump and Stokes laser beams were attenuated by 
using neutral-density filter wheels to 40 mW and 20 mW at the sample when using the 
20x objective, and 20 mW and 20 mW at the sample when using the 60x objective. For 
CARS and SFG imaging of histology slides, the average powers of the pump and Stokes 
laser beams were attenuated to 10 mW and 5 mW at the sample using the 20x objective. 
There was no noticeable photodamage to the samples throughout the imaging processes.  
To visualize the tumor architectures with 3D cellular and subcellular resolution, 
we directly placed tissues of different thickness around 5 mm on a glass surface such that 
a relatively flat tissue surface faces the 60x water immersion objective on an inverted 
microscope. When the beating frequency was set to the specified 2840 cm-1, substantial 







4.2.5 Quantitative Analysis of Collagen Density Surrounding Tumor Mass 
An analysis volume was defined with the dimensions of 250 µm (x) × 250 µm (y) 
× 30 µm (z), with z = 0 being the tumor mass and collagen interface. For each analysis 
volume, 31 frames along the z-axis with a fixed step size of 1 µm were acquired. Six 
different volumes were evaluated, and the total SFG intensity from 186 frames (6 × 31 
frames) was used to infer the mammary stromal collagen density surrounding tumor mass. 




4.3.1 Significant Components of Mammary Tissues Visualized with Label-free 
CARS/SFG Imaging 
Since CARS is sensitive to lipids, which are a main component of the cytoplasmic 
LDs, cell membranes, and intracellular membranes, we used CARS to depict morphology 
of various cell types in mammary tissues. We observed substantial CARS signals arising 
from the cell membranes and cytoplasmic LDs, but only weak CARS signals from the 
lipid-poor cell nuclei (Figure 4.2A), a contrast indicating significantly enhanced 
visualization of cell morphology.  Thus, CARS images enabled the identification of 
various cell types based on cell morphology and nucleus-cytoplasm ratio. For instance, 
mammary tumor cells were identified by a round shape and a large nucleus-cytoplasm 
ratio. The tumor cell nucleus and membrane were confirmed by Hoechst 33342 (Figure 
4.3A-C) and DIOC18 (Figure 4.3D-E) staining, respectively. Adipocytes were identified 








Figure 4.2 CARS and SFG imaging of significant components of the 
mammary tumor and stroma (Red: CARS; Green: SFG). (A) CARS image of 
tumor cells whose signal comes from lipid-rich cell membrane. (B) 
Adipocytes among dense collagen fibrils. (C-D) 3D images of blood vessels 
surrounded by parallel collagen fibrils. Scale bars: 25 µm. 
 
structures shown in depth-resolved CARS images (Figure 4.2C-D), which were 
confirmed by FITC-IB4 labeling (Figure 4.4). In addition to various types of cells, we 
observed dense type I collagen fibrils surrounded by adipocytes (Figure 4.2B) and 
paralleled with blood vessels (Figure 4.2C-D). These findings demonstrate that 
CARS/SFG imaging allows label-free evaluation of mammary tissue architecture, 








4.3.2 CARS/SFG Imaging of Normal Tissue, Adenoma, and Adenocarcinoma of 
Mammary Glands in Histology Samples 
To determine whether CARS/SFG imaging could identify normal mammary gland, 
adenomas, and adenocarcinomas, we studied well-defined histology slides of mammary 
tissues. While considerable forward CARS signals arose from the unfilled areas on 
histology slides, including LDs within adipocytes, cell nuclei gave significant negative 
contrast because Haematoxylin, which was used for cell nuclei staining, absorbed most of 
the incident light. For the same reason, eosin-stained cytoplasm and ECM can be seen 
under CARS microscopy. Thus, CARS enabled us to depict the morphology of the 
histological specimen.  SFG was used for selective imaging of type I collagen fibrils.  
Compared with histological images of normal mammary gland, adenomas and 
adenocarcinomas (Figure 4.5A-C, respectively), the merged CARS and SFG images of 
corresponding histology slides (Figure 4.5D-F, respectively) specifically depicted 
morphological characteristics of normal mammary gland, mammary adenomas and 
adenocarcinomas. Density and organization of collagen fibrils surrounding epithelial cells 
provided the first identification marker. In the normal mammary glands and mammary 
adenomas, dense wavy collagen fibrils paralleling the ductal profile formed an integral 
scaffold to support the ductal cells. In contrast, the tumor mass in mammary 
adenocarcinomas was surrounded by thin and disorganized collagen fibrils. In addition, 
the extent of cell proliferation could be used as the second identification marker. The 









Figure 4.3 Confirm CARS observation of tumor cells by Hoechst33342 and 
DIOC18 labeling. (A, D) CARS image of tumor cells whose signal comes 
from lipid-rich cell membranes. (B) TPEF image of tumor cell nuclei labeled 
with Hoechst33342. (C) Merged image of A and B (red: CARS; green: TPEF). 
(E) TPEF image of tumor cell membrane labeled with DIOC18. Scalar bars: 
25 µm. 
 
multilayered epithelium in mammary tumors. Moreover, whereas the tumor mass was 
still localized in adenomas, tumor cells proliferated out of control and invaded the 
surrounding stroma in adenocarcinomas. 
 
4.3.3 CARS/SFG Imaging of Intact Normal tissue, Adenoma, and Adenocarcinoma of 
Mammary Glands 
The criteria established in the CARS/SFG images of histology slides were used to 
study unstained mammary tissues. The label-free CARS and SFG images of the intact 








Figure 4.4 Confirm CARS observation of blood vessels by FITC-IB4 labeling. 
(A) CARS image of tumor cells and endothelial cells. (B) TPEF image of a 
blood vessel labeled with FITC-IB4. (C) SFG image of collagen fibrils. (D) 
CARS image (red) of the blood vessel is colocalized with TPEF (green) image. 
The blood vessel is protected by collagen fibrils (blue). Scalar bars: 25 µm. 
 
observed from standard light microscopy of histological slides (Figure 4.6B).  Based on 
these images, we were able to observe a single layer of epithelia on the innermost part of 
the duct. Bunches of mature collagen with a wavy fibrillar appearance tend to wrap 
concentrically around the duct and show a typical orientation of their long axis 
paralleling the duct. Outside the collagen are orderly arranged adipocytes with one giant 
LD per cell. In the zoom-in CARS image of the ductal cells, the single layer of columnar 









Figure 4.5 Validating CARS/SFG imaging as a tool to identify the normal 
mammary gland, mammary adenomas and adenocarcinomas. (A-C) H&E 
stained histology images of normal mammary gland, mammary adenoma and 
adenocarcinoma, respectively. Scale bars: 100 µm. (D-F) CARS and SFG 
images of histology slides from normal mammary gland, mammary adenoma 
and adenocarcinoma, respectively. Scale bars: 75 µm. 
 
We further characterized mammary tumor tissues with the CARS/SFG imaging 
system. 3D images of adenomas showed that abundant wavy collagen fibrils formed a 
smooth outer contour that concentrically wrapped around the small cluster of tumor cells. 
These cells had a low cuboidal shape with enlarged nuclei and were in close proximity to 
each other (Figure 4.6D-F). The well-defined collagen boundary around the localized 
tumor mass was indicative of the tumor’s benign nature.  On the contrary, tumor cells in 
the adenocarcinoma showed a ragged contour without an organized concentric wrap of 
collagen (Figure 4.6G-I). These malignant tumor cells had a similar shape and size as 








Figure 4.6 Label-free CARS and SFG imaging of normal mammary gland, 
mammary adenoma and adenocarcinoma in intact tissues (Red: CARS; Green: 
SFG). (A-C). Representative CARS and SFG images of unstained normal 
mammary gland ex vivo. Single-layer ductal cells are wrapped concentrically 
by bunches of wavy collagen fibrils (A, asterisk). Outside are orderly arranged 
adipocytes marked with “a” in A. The same features observed in intact tissue 
(A) are confirmed by the corresponding histological pattern (B). The box 
shown in A was magnified in C, which permits the single-cell resolution 
imaging of ductal cells (arrow head). Scale bars: 50 µm.  (D-F) 3D images of 
adenoma show that abundant wavy collagen fibrils form a smooth organized 
outer contour (arrow heads) to concentrically wrap around the localized tumor 
mass. (G-I) Straight collagen fibrils usually observed either within (G, arrow) 
or perpendicularly against (H, I, asterisk) the tumor mass. The triangles in H 








4.3.4 Quantitative Analysis of Collagen Density Surrounding Tumor Mass 
 
Figure 4.7 Quantitative analysis of collagen density surrounding tumor mass. 
Analysis of three pairs of adenoma and adenocarcinoma shows that adenoma 
has an average 4-fold higher collagen density surrounding tumor mass than 
adenocarcinoma. (Inset: simplified model that defines the dimensions of 
imaging; see details in Experimental Section.) 
 
straight collagen fibrils usually observed either within (Figure 4.6G) or perpendicularly 
against (Figure 4.6H-I) the tumor mass. The straight collagen fibrils may act as 
“highways” enabling malignant tumor cells to migrate and invade towards the 
vasculature [381]. In addition to collagen organization, another factor that distinguished 
adenoma from adenocarcinoma was collagen density surrounding the tumor mass. A 
significant reduction of collagen density was observed in adenocarcinomas relative to 
adenomas. The mammary tumor status identified by the CARS/SFG imaging system was 
verified by the histological analysis of corresponding mammary tissues blindly. 
To confirm that collagen density surrounding the tumor mass decreases in 
aggressive tumors, we quantitatively analyzed the collagen density surrounding 







concentration of type I collagen fibrils, we evaluated the relative collagen density of a 
tissue based on total SFG intensity. To systematically compare the collagen density 
between adenoma and adenocarcinoma, we defined a fixed analysis volume starting from 
the tumor mass-collagen interface and collected total SFG signals from six volumes in 
the mammary tumor tissues of each tumor (see Experimental Section; Figure 4.7). 
Consistent with our observation, quantitative analysis of SFG intensity indicated that 
mammary adenocarcinomas show a decrease in collagen density surrounding tumor mass 
by an average of 4-fold relative to mammary adenoma. 
 
4.4 Discussion 
We have distinguished normal mammary epithelial cells and mammary tumor 
cells based on the morphological information provided by CARS imaging. Whereas 
normal epithelial cells grew in a columnar shape with small nuclei and formed a single 
layer, tumor cells developed a round shape with large nuclei and proliferated into a 
multilayer cluster (Figure 4.6). Thus, our identification of tumor cells is based on the 
morphology and arrangement of epithelial cells. Because the CARS signals are generated 
from symmetric CH2 stretch vibration, our method does not require any labeling and 
therefore avoids the common problem of photobleaching in fluorescence microscopy.  
Although CARS was able to identify normal epithelial cells and tumor cells, it 
could not differentiate adenoma and adenocarcinoma by itself. Thus, we integrated 
CARS with SFG on the same platform, so that we were able to take advantages of both 
CARS and SFG to comprehensively characterize mammary tissues. SFG has been used to 







dense wavy collagen fibrils in normal mammary gland and mammary adenoma, as 
opposed to the thin straight collagen fibrils in mammary adenocarcinoma (Figure 4.6). 
These findings suggest that, in addition to morphological characteristics of epithelial cells, 
density and organization of type I collagen fibrils can also be evaluated as a crucial 
signature of tumor progression. Therefore, simultaneous CARS and SFG imaging of 
mammary tissues can indeed offer more comprehensive information compared to each 
individual technique. Our results have demonstrated that multimodal CARS/SFG imaging 
is able to accurately differentiate adenoma from adenocarcinoma in rat mammary tissues, 
based on morphology and arrangement of epithelial cells and 3D organization of type I 
collagen fibrils. 
Several previous studies have shown that aberrations in type I collagen production 
and degradation have become one of the hallmarks of tumor stroma [384]. The 
observation of reduced collagen density in adenocarcinoma relative to adenoma is 
consistent with previous findings on proteases that degrade ECM in tumor environment 
[384]. More interestingly, Provenzano et al. defined tumor-associated collagen signatures 
to locate and characterize mammary tumors [385, 386]. In particular, Provenzano et al. 
claimed that collagen reorganization at the tumor-stromal interface facilitates local 
invasion [385]. So far, however, few studies have discussed straight collagen fibrils 
present in mammary adenocarcinoma. It is possible that collagenases and proteases play 
important roles in the formation of straight collagen fibrils to further facilitate tumor cell 
migration and invasion. The mechanisms underlying straight collagen formation need to 







In this work, multimodal CARS/SFG imaging has shown the potential of 
intraoperative assessment of tumor margins. With a penetration depth of tens of microns 
and subcellular spatial resolution, CARS/SFG imaging provides a new contrast other than 
histology and enables us to identify tumor cells and their malignancy near the margin. 
Unlike histology, CARS/SFG imaging does not need any labeling agents, so that 
decisions can be made during the surgery. As a result, most normal tissues can be 
maintained with a negative margin.  Furthermore, improvements in intraoperative margin 
assessment can significantly reduce local recurrence and distant metastasis induced by 
positive margins and re-excisions usually observed after lumpectomy. In order to achieve 
intraoperative margin assessment in situ by CARS/SFG imaging, the imaging system 
needs to be more compact by application of fiber lasers.  The compact CARS/SFG 
imaging system could assist pathologists in making decisions and help surgeons remove 
entire malignant tumor tissues, while saving as much normal tissues as possible, within a 








CHAPTER 5. OUTLOOK 
5.1 Cholesterol Metabolism in Cancer 
Our study has identified cholesterol esterification as a potential marker and 
therapeutic target of advanced PCa. Our next step, therefore, is to first validate the 
presence of altered cholesterol metabolism in human PCa patient specimens and prove 
the accumulation of CEs correlates with the clinical outcomes of PCa patients. We will 
then elucidate the mechanism linking cholesterol metabolism with cancer aggressiveness, 
and evaluate the therapeutic benefit of CE depletion in preclinical animal models of PCa. 
At the completion of this project, it is our expectation that we will have provided strong 
evidence to support the concept that inhibition of cholesterol accumulation is a viable and 
potentially attractive therapeutic intervention strategy to treat advanced PCa. Notably, 
several small molecule inhibitors of cholesterol accumulation, e.g. avasimibe, have been 
approved by FDA to treat atherosclerosis but failed due to the lack of effectiveness. Our 
proposed study would demonstrate a novel use of existing drugs to treat advanced PCa, 
and it is anticipated that preclinical studies and/or clinical trials will follow shortly after 
the completion of this project. Ultimately, the adoption of such strategy will substantially 
improve the clinical outcome for metastatic PCa patients that are resistant to hormone 
therapy. Our deeper mechanistic study will contribute to the understanding of 







biological foundation of targeting cholesterol accumulation for treatment of metastatic 
PCa.  
The long term goal of our project on cholesterol metabolism in cancer is to 
develop strategies that enable early diagnosis of aggressive tumors using elevated 
cholesterol metabolites as molecular markers, as well as suppression of cancer 
aggressiveness by modulating cholesterol metabolism pathways. Because the PI3K 
pathway is hyperactivated not only in advanced PCa, but also in many other human 
cancers, including brain, breast, renal, lymphocyte, cervical, and lung [67], cholesterol 
accumulation might be a common characteristic of PI3K-driven cancers. Future analysis 
of various types of human cancer tissues will validate whether CE is indeed a hallmark of 
PI3K-driven cancers, and whether CE can be used as a prognostic marker to predict 
cancer aggressiveness.  Future elucidation of the molecular mechanisms by which PI3K 
pathway differentially regulates cholesterol metabolism in cancer cells from multiple 
tissues of origin will determine whether CE is a compelling drug target across multiple 
cancer types.  
 
5.2 Membrane Lipids in Cancer 
Based on the results of our study, we expect that analysis of apical polarity in live 
human mammary acini using Raman spectromicroscopy provides an effective screening 
platform to identify risk or protective factors that initiate or prevent breast cancer. We 
will achieve this goal with the following two steps.  
The first step is to identify breast cancer risk and protective factors using Raman 







breast cancer development [42, 387]  Fatty acids are delivered to mammary cells mainly 
by uptake of LDL [263]. Dietary interventions of fatty acids can lead to rapid and 
potentially beneficial changes in ω3/ω6 PUFA ratio of serum and breast adipose tissue 
[345, 346]. The adipokines are a number of adipocyte-secreted polypeptides that have 
been associated with obesity and insulin resistance [42, 387]. However, a consensus is 
lacking on the impact of certain dietary fatty acids or adipokines on primary prevention 
of breast cancer [42, 388-390]. Our study has shown the capability of Raman 
spectromicroscopy to monitor the dynamic changes of apical polarity of the same acini 
over time. We will continue to test if Raman based screening platform could accurately 
and effectively determine the effects of a panel of dietary fatty acids and adipokines on 
apical polarity of mammary acini. Combinations of identified risk and potential 
protective factors will be further assessed to evaluate the preventative potential of the 
protective factors.  
The second step is to reveal the impact of the identified risk and protective factors 
on the expression of apical polarity-associated genes. Recent findings have revealed that 
the status of apical polarity influences two genes of particular interest: PDPK1 and CDS1 
(unpublished data, Lelièvre lab). PDPK1 functions downstream of PI3K through 
PDPK1's interaction with membrane phospholipids.[391] Although PDPK1 is known to 
be overexpressed in breast cancer,[391, 392] it has just been found to be upregulated 
when apical polarity is disrupted by AGA reagent, an inhibitor of gap junctional 
intercellular communication. CDS1 is an important precursor for the synthesis of 
phosphatidylinositol, whose phosphorylation plays an important role in lipid signaling 







by AGA reagent. By simultaneously measuring membrane lipid phase and expression of 
PDPK1 or CDS1 of the same acini over time, we will evaluate the change of PDPK1 or 
CDS1 expression when apical polarity is altered by identified risk factors or when apical 
polarity is restored by combining protective factors with the risk factors. This endeavor 
will determine whether PDPK1 or CDS1 is involved in the apical polarity alteration 
induced by the risk factors. The involvement of apical polarity-associated genes builds up 
a molecular basis for the impact of risk and protective factors on apical polarity of 
mammary acini, which may assist future mechanistic studies.  
Finally, our approach could be extended to a multi-well plate on a dual scanning 
Raman spectromicroscope for high-throughput screening of numerous compounds and 
drugs. Future systematic study along this direction will help the design of better primary 
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